US20030232869A1 - N3 alkylated benzimidazole derivatives as MEK inhibitors - Google Patents
N3 alkylated benzimidazole derivatives as MEK inhibitors Download PDFInfo
- Publication number
- US20030232869A1 US20030232869A1 US10/387,879 US38787903A US2003232869A1 US 20030232869 A1 US20030232869 A1 US 20030232869A1 US 38787903 A US38787903 A US 38787903A US 2003232869 A1 US2003232869 A1 US 2003232869A1
- Authority
- US
- United States
- Prior art keywords
- aryl
- heteroaryl
- heterocyclyl
- alkyl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C.[2*]C.[7*]C.[8*]C1=CC=C(NC2=C([W])C([10*])=C3ncnC3=C2[9*])C=C1 Chemical compound [1*]C.[2*]C.[7*]C.[8*]C1=CC=C(NC2=C([W])C([10*])=C3ncnC3=C2[9*])C=C1 0.000 description 16
- XRRCKHBWBKURDL-UHFFFAOYSA-N CC(C)COCCON Chemical compound CC(C)COCCON XRRCKHBWBKURDL-UHFFFAOYSA-N 0.000 description 2
- YBDTXIFFOBBBJI-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)N2CCNCC2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)N2CCNCC2)C=C2NC=NC2=C1F YBDTXIFFOBBBJI-UHFFFAOYSA-N 0.000 description 2
- SCAKCPCDQRTARN-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCC=O Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCC=O SCAKCPCDQRTARN-UHFFFAOYSA-N 0.000 description 2
- XEVLUMORBBHORF-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCS(C)(=O)=O Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCS(C)(=O)=O XEVLUMORBBHORF-UHFFFAOYSA-N 0.000 description 2
- CGFANNYMWDBFSS-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CC(O)CO Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CC(O)CO CGFANNYMWDBFSS-UHFFFAOYSA-N 0.000 description 2
- HHCJZHMWRPZKCV-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCCC1 Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCCC1 HHCJZHMWRPZKCV-UHFFFAOYSA-N 0.000 description 2
- JBUSDIGQEGFAAQ-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=NC2=C1F JBUSDIGQEGFAAQ-UHFFFAOYSA-N 0.000 description 2
- JZPPTLAOVLYFAW-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C2=NN=C(O)O2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C2=NN=C(O)O2)C=C2NC=NC2=C1F JZPPTLAOVLYFAW-UHFFFAOYSA-N 0.000 description 2
- ILWZVBWRPVFJQL-UHFFFAOYSA-N CC1=NC(CN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCCO)C=C32)=CS1 Chemical compound CC1=NC(CN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCCO)C=C32)=CS1 ILWZVBWRPVFJQL-UHFFFAOYSA-N 0.000 description 2
- LWMHCMFJDKKXSZ-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C(=O)NOC(C)(C)CO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C(=O)NOC(C)(C)CO)C=C21 LWMHCMFJDKKXSZ-UHFFFAOYSA-N 0.000 description 2
- CAHNBVQDWMPDEF-UHFFFAOYSA-N CN1CCN(CCCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)CC1 Chemical compound CN1CCN(CCCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)CC1 CAHNBVQDWMPDEF-UHFFFAOYSA-N 0.000 description 2
- UYQIXMTYZKYDNG-UHFFFAOYSA-N CNC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound CNC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 UYQIXMTYZKYDNG-UHFFFAOYSA-N 0.000 description 2
- LAKBOMWCBSJUJP-UHFFFAOYSA-N CNC(=O)C1=C(NC2=CC=C(Cl)C=C2C)C(F)=C2N=CNC2=C1 Chemical compound CNC(=O)C1=C(NC2=CC=C(Cl)C=C2C)C(F)=C2N=CNC2=C1 LAKBOMWCBSJUJP-UHFFFAOYSA-N 0.000 description 2
- VEJZIIGBEZHTRF-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCCl)C2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCCl)C2=C1 VEJZIIGBEZHTRF-UHFFFAOYSA-N 0.000 description 2
- PNCPSEVJGXTDAC-UHFFFAOYSA-N COC1=CC=C(CN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCCO)C=C32)C=C1 Chemical compound COC1=CC=C(CN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCCO)C=C32)C=C1 PNCPSEVJGXTDAC-UHFFFAOYSA-N 0.000 description 2
- YQLWJKUPRNTNFB-UHFFFAOYSA-N COCCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 Chemical compound COCCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 YQLWJKUPRNTNFB-UHFFFAOYSA-N 0.000 description 2
- QYBOQIGYQVNACV-UHFFFAOYSA-N CS(=O)(=O)CCCON Chemical compound CS(=O)(=O)CCCON QYBOQIGYQVNACV-UHFFFAOYSA-N 0.000 description 2
- YYCYAKAWUKAKQW-UHFFFAOYSA-N CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C3=NN=C(N)O3)C=C21 Chemical compound CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C3=NN=C(N)O3)C=C21 YYCYAKAWUKAKQW-UHFFFAOYSA-N 0.000 description 2
- AUIOCNWYVCGOMP-UHFFFAOYSA-N CS(=O)(=O)CCON Chemical compound CS(=O)(=O)CCON AUIOCNWYVCGOMP-UHFFFAOYSA-N 0.000 description 2
- GWPHAJCZGHIQFN-UHFFFAOYSA-N CSCCCON Chemical compound CSCCCON GWPHAJCZGHIQFN-UHFFFAOYSA-N 0.000 description 2
- AZJFCYYSANYIHB-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCN3CCOCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCN3CCOCC3)C2=C1 AZJFCYYSANYIHB-UHFFFAOYSA-N 0.000 description 2
- ZDVUPQBDDSLGDJ-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3CCOCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3CCOCC3)C2=C1 ZDVUPQBDDSLGDJ-UHFFFAOYSA-N 0.000 description 2
- UBEOBEUUUKHITB-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 UBEOBEUUUKHITB-UHFFFAOYSA-N 0.000 description 2
- OQGNPAHKVYYBDA-UHFFFAOYSA-N C#CC1=CC=C(NC2=C(C(=O)N3CCNCC3)C=C3NC=NC3=C2F)C(C)=C1 Chemical compound C#CC1=CC=C(NC2=C(C(=O)N3CCNCC3)C=C3NC=NC3=C2F)C(C)=C1 OQGNPAHKVYYBDA-UHFFFAOYSA-N 0.000 description 1
- GIFKUEOUBZNPPO-UHFFFAOYSA-N C#CC1=CC=C(NC2=C(C(=O)NOCC3CC3)C=C3NC=NC3=C2F)C(C)=C1 Chemical compound C#CC1=CC=C(NC2=C(C(=O)NOCC3CC3)C=C3NC=NC3=C2F)C(C)=C1 GIFKUEOUBZNPPO-UHFFFAOYSA-N 0.000 description 1
- KHNUUHJZXDCSCB-UHFFFAOYSA-N C=CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound C=CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)NOCC3CC3)C=C21 KHNUUHJZXDCSCB-UHFFFAOYSA-N 0.000 description 1
- PXOVQHGHQSCAKZ-UHFFFAOYSA-N C=CCCCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound C=CCCCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 PXOVQHGHQSCAKZ-UHFFFAOYSA-N 0.000 description 1
- FMXBOHKDNTVBQJ-UHFFFAOYSA-N C=CCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound C=CCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)NOCC3CC3)C=C21 FMXBOHKDNTVBQJ-UHFFFAOYSA-N 0.000 description 1
- YKTCOYUDKDFQJC-UHFFFAOYSA-N C=CCCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound C=CCCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 YKTCOYUDKDFQJC-UHFFFAOYSA-N 0.000 description 1
- TUDJOZJMTVVPQE-UHFFFAOYSA-N C=CCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 Chemical compound C=CCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 TUDJOZJMTVVPQE-UHFFFAOYSA-N 0.000 description 1
- NBAOMYLIBHGXFS-UHFFFAOYSA-N C=CCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound C=CCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 NBAOMYLIBHGXFS-UHFFFAOYSA-N 0.000 description 1
- HFXJPEVIDTXKFU-UHFFFAOYSA-N C=CCN1C=NC2=CC(C(=O)NOCC3CC3)=C(NC3=CC=C(Cl)C=C3C)C(F)=C21 Chemical compound C=CCN1C=NC2=CC(C(=O)NOCC3CC3)=C(NC3=CC=C(Cl)C=C3C)C(F)=C21 HFXJPEVIDTXKFU-UHFFFAOYSA-N 0.000 description 1
- VTMPNEJTPSGCAW-UHFFFAOYSA-N C=CCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 Chemical compound C=CCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 VTMPNEJTPSGCAW-UHFFFAOYSA-N 0.000 description 1
- BCWYGJFLYOGMIF-UHFFFAOYSA-N C=COCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCCl)C2=C1 Chemical compound C=COCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCCl)C2=C1 BCWYGJFLYOGMIF-UHFFFAOYSA-N 0.000 description 1
- PPFSNDLGAIPBNV-UHFFFAOYSA-N CB(O)N(C)CCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 Chemical compound CB(O)N(C)CCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 PPFSNDLGAIPBNV-UHFFFAOYSA-N 0.000 description 1
- VFKAWJYDRNMREJ-UHFFFAOYSA-N CC(C)(CO)ONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCCCO3)C2=C1 Chemical compound CC(C)(CO)ONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCCCO3)C2=C1 VFKAWJYDRNMREJ-UHFFFAOYSA-N 0.000 description 1
- WFHYXEJTZPZCPI-UHFFFAOYSA-N CC(C)(CO)ONC(=O)C1=C(NC2=CC=C(Br)C=C2F)C(F)=C2N=CN(CC3CCCCO3)C2=C1 Chemical compound CC(C)(CO)ONC(=O)C1=C(NC2=CC=C(Br)C=C2F)C(F)=C2N=CN(CC3CCCCO3)C2=C1 WFHYXEJTZPZCPI-UHFFFAOYSA-N 0.000 description 1
- CGKODIXPIKTPDV-UHFFFAOYSA-N CC(C)CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CC(C)CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 CGKODIXPIKTPDV-UHFFFAOYSA-N 0.000 description 1
- FTERZDMHNVISAC-UHFFFAOYSA-N CC(C)COCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 Chemical compound CC(C)COCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 FTERZDMHNVISAC-UHFFFAOYSA-N 0.000 description 1
- GYUGTZKSJKSDJM-UHFFFAOYSA-N CC(C)N1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CC(C)N1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 GYUGTZKSJKSDJM-UHFFFAOYSA-N 0.000 description 1
- NKTSGCHAMRQQBJ-UHFFFAOYSA-N CC(C)N1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CC(C)N1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 NKTSGCHAMRQQBJ-UHFFFAOYSA-N 0.000 description 1
- KECRJTIVYVFVCQ-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)N2CCC(N)C2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)N2CCC(N)C2)C=C2NC=NC2=C1F KECRJTIVYVFVCQ-UHFFFAOYSA-N 0.000 description 1
- RNUJPNFTMPEXKP-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2C Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2C RNUJPNFTMPEXKP-UHFFFAOYSA-N 0.000 description 1
- VJRDJNUEWZYUES-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CC1=CN=CO1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CC1=CN=CO1 VJRDJNUEWZYUES-UHFFFAOYSA-N 0.000 description 1
- TUBGPIYSYJYHPP-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCC(O)CO Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCC(O)CO TUBGPIYSYJYHPP-UHFFFAOYSA-N 0.000 description 1
- REOHQYCHCYSBDC-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCC(N(C)C)C1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCC(N(C)C)C1 REOHQYCHCYSBDC-UHFFFAOYSA-N 0.000 description 1
- OKQGDPZNZJWJRT-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCCCC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCCCC1 OKQGDPZNZJWJRT-UHFFFAOYSA-N 0.000 description 1
- RKMSPTGRDIAOBR-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCN(C)CC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCN(C)CC1 RKMSPTGRDIAOBR-UHFFFAOYSA-N 0.000 description 1
- NZTLDAQNRTZHPF-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCNCC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCNCC1 NZTLDAQNRTZHPF-UHFFFAOYSA-N 0.000 description 1
- WLVAPVNOGQRRBF-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCOCC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCOCC1 WLVAPVNOGQRRBF-UHFFFAOYSA-N 0.000 description 1
- MVIFQMJLEDLACG-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCS(=O)(=O)CC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCS(=O)(=O)CC1 MVIFQMJLEDLACG-UHFFFAOYSA-N 0.000 description 1
- HOTSYQQBXFSFLN-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCSCC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCSCC1 HOTSYQQBXFSFLN-UHFFFAOYSA-N 0.000 description 1
- YFZYVAPCPNVICN-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCNC(C)C Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCNC(C)C YFZYVAPCPNVICN-UHFFFAOYSA-N 0.000 description 1
- WJOOBGBDXCCVAY-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCNCC1=NC=CC=C1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCNCC1=NC=CC=C1 WJOOBGBDXCCVAY-UHFFFAOYSA-N 0.000 description 1
- SOWLDHIIHNPGIW-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCN1CCCCC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCN1CCCCC1 SOWLDHIIHNPGIW-UHFFFAOYSA-N 0.000 description 1
- DOSXQKRBIUOSNN-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCN1CCN(C)CC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCN1CCN(C)CC1 DOSXQKRBIUOSNN-UHFFFAOYSA-N 0.000 description 1
- AMXRQFBOLAVTLX-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCN1CCNCC1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCN1CCNCC1 AMXRQFBOLAVTLX-UHFFFAOYSA-N 0.000 description 1
- JQPCMRKNPPYJRM-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCNC(C)C Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCNC(C)C JQPCMRKNPPYJRM-UHFFFAOYSA-N 0.000 description 1
- OEWPLOAZLGNSPN-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCS(=O)(=O)C1=CC=CC=C1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCS(=O)(=O)C1=CC=CC=C1 OEWPLOAZLGNSPN-UHFFFAOYSA-N 0.000 description 1
- DHZGVPNAMLHFJL-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=NC2=C1F DHZGVPNAMLHFJL-UHFFFAOYSA-N 0.000 description 1
- MCQLUINOFWEFBC-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)O)C=C2C(=C1F)N=CN2CCS(=O)(=O)C1=CC=CC=C1 Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)O)C=C2C(=C1F)N=CN2CCS(=O)(=O)C1=CC=CC=C1 MCQLUINOFWEFBC-UHFFFAOYSA-N 0.000 description 1
- HMEATISAVSVPGG-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C(=O)O)C=C2C(=C1F)N=CN2CCS(C)(=O)=O Chemical compound CC1=CC(Br)=CC=C1NC1=C(C(=O)O)C=C2C(=C1F)N=CN2CCS(C)(=O)=O HMEATISAVSVPGG-UHFFFAOYSA-N 0.000 description 1
- XHHGPLBYQFIILA-UHFFFAOYSA-N CC1=CC(Br)=CC=C1NC1=C(C2=NN=C(N)O2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Br)=CC=C1NC1=C(C2=NN=C(N)O2)C=C2NC=NC2=C1F XHHGPLBYQFIILA-UHFFFAOYSA-N 0.000 description 1
- ZKTSDHHLLBLUMD-UHFFFAOYSA-N CC1=CC(C#N)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=NC2=C1F Chemical compound CC1=CC(C#N)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=NC2=C1F ZKTSDHHLLBLUMD-UHFFFAOYSA-N 0.000 description 1
- VWMLFNSYMIGDPB-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NCC2=NC=CC=C2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NCC2=NC=CC=C2)C=C2NC=NC2=C1F VWMLFNSYMIGDPB-UHFFFAOYSA-N 0.000 description 1
- BSRFSBIASPXCBN-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NCCC2=NC=CC=C2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NCCC2=NC=CC=C2)C=C2NC=NC2=C1F BSRFSBIASPXCBN-UHFFFAOYSA-N 0.000 description 1
- JCQMQOWXNIGTAT-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NN)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NN)C=C2NC=NC2=C1F JCQMQOWXNIGTAT-UHFFFAOYSA-N 0.000 description 1
- DVIZCUIJAJSXJB-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOC(C)(C)C)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOC(C)(C)C)C=C2NC=NC2=C1F DVIZCUIJAJSXJB-UHFFFAOYSA-N 0.000 description 1
- IOZGMIVBAXEAAF-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2=CC=CC=C2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2=CC=CC=C2)C=C2NC=NC2=C1F IOZGMIVBAXEAAF-UHFFFAOYSA-N 0.000 description 1
- DGRXLJVXUZHOPA-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2C Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2C DGRXLJVXUZHOPA-UHFFFAOYSA-N 0.000 description 1
- ZOZGFJAIHCYQKK-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCC(O)CO Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCC(O)CO ZOZGFJAIHCYQKK-UHFFFAOYSA-N 0.000 description 1
- MJIVXIVEQLMKQR-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCN(C)CC1 Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCN(C)CC1 MJIVXIVEQLMKQR-UHFFFAOYSA-N 0.000 description 1
- BCSQWIMJMMTEJT-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCOCC1 Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCCN1CCOCC1 BCSQWIMJMMTEJT-UHFFFAOYSA-N 0.000 description 1
- WIDALVMXYUPSTC-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCN(C)C Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCCN(C)C WIDALVMXYUPSTC-UHFFFAOYSA-N 0.000 description 1
- JRGJLOTTXOHMMQ-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCN(C)C Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCN(C)C JRGJLOTTXOHMMQ-UHFFFAOYSA-N 0.000 description 1
- ZCYXZXZAIDXIPB-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCN1CCCC1 Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCN1CCCC1 ZCYXZXZAIDXIPB-UHFFFAOYSA-N 0.000 description 1
- YDAVDTJRFDKOAW-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCN1CCN(C)CC1 Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2C(=C1F)N=CN2CCN1CCN(C)CC1 YDAVDTJRFDKOAW-UHFFFAOYSA-N 0.000 description 1
- XEEUWMIUBKUCCF-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2N=CN(C)C2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2N=CN(C)C2=C1F XEEUWMIUBKUCCF-UHFFFAOYSA-N 0.000 description 1
- ZHUPJVOXWCPCPW-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2N=CN(CC(O)CO)C2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2N=CN(CC(O)CO)C2=C1F ZHUPJVOXWCPCPW-UHFFFAOYSA-N 0.000 description 1
- KHFGGXCQFLDBBO-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=N(CCCCN3CCCC3)C2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=N(CCCCN3CCCC3)C2=C1F KHFGGXCQFLDBBO-UHFFFAOYSA-N 0.000 description 1
- XIJJIJXRPGDIAS-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C2=NN=C(N)O2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C2=NN=C(N)O2)C=C2NC=NC2=C1F XIJJIJXRPGDIAS-UHFFFAOYSA-N 0.000 description 1
- POFMBQQKXKZDGE-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C2=NN=C(S)O2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C2=NN=C(S)O2)C=C2NC=NC2=C1F POFMBQQKXKZDGE-UHFFFAOYSA-N 0.000 description 1
- XLKSPIQMWOSKMU-UHFFFAOYSA-N CC1=CC(Cl)=CC=C1NC1=C(C2=NN=CO2)C=C2NC=NC2=C1F Chemical compound CC1=CC(Cl)=CC=C1NC1=C(C2=NN=CO2)C=C2NC=NC2=C1F XLKSPIQMWOSKMU-UHFFFAOYSA-N 0.000 description 1
- VGYLISVORIWOFD-UHFFFAOYSA-N CC1=CC(OC(F)(F)F)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=NC2=C1F Chemical compound CC1=CC(OC(F)(F)F)=CC=C1NC1=C(C(=O)NOCC2CC2)C=C2NC=NC2=C1F VGYLISVORIWOFD-UHFFFAOYSA-N 0.000 description 1
- QKVXJFIPLVCERB-UHFFFAOYSA-N CC1=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C2N1 Chemical compound CC1=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C2N1 QKVXJFIPLVCERB-UHFFFAOYSA-N 0.000 description 1
- KIADNHUPLZQEAA-UHFFFAOYSA-N CCC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound CCC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 KIADNHUPLZQEAA-UHFFFAOYSA-N 0.000 description 1
- VIMLMBRPIZTEFR-UHFFFAOYSA-N CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)NOCC3CC3)C=C21 VIMLMBRPIZTEFR-UHFFFAOYSA-N 0.000 description 1
- CBSTUIFMBXYWOA-UHFFFAOYSA-N CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 CBSTUIFMBXYWOA-UHFFFAOYSA-N 0.000 description 1
- SBVKWNLWCDMMIR-UHFFFAOYSA-N CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 SBVKWNLWCDMMIR-UHFFFAOYSA-N 0.000 description 1
- YIWBUIBYHONTKD-UHFFFAOYSA-N CCCNC(=O)C1=C(NC2=CC=C(Br)C=C2C)C(F)=C2N=CNC2=C1 Chemical compound CCCNC(=O)C1=C(NC2=CC=C(Br)C=C2C)C(F)=C2N=CNC2=C1 YIWBUIBYHONTKD-UHFFFAOYSA-N 0.000 description 1
- ANQAYTRIMBMKIC-UHFFFAOYSA-N CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 ANQAYTRIMBMKIC-UHFFFAOYSA-N 0.000 description 1
- DWKQDJBSWQIGFW-UHFFFAOYSA-N CCOCC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound CCOCC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 DWKQDJBSWQIGFW-UHFFFAOYSA-N 0.000 description 1
- ZQSJGSGAIUCJSE-UHFFFAOYSA-N CCOCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CCOCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 ZQSJGSGAIUCJSE-UHFFFAOYSA-N 0.000 description 1
- NZRUUOLYENQEBU-UHFFFAOYSA-N CCOCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CCOCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 NZRUUOLYENQEBU-UHFFFAOYSA-N 0.000 description 1
- UOJCDCFHPCEEQC-UHFFFAOYSA-N CN(C)CCCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CN(C)CCCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 UOJCDCFHPCEEQC-UHFFFAOYSA-N 0.000 description 1
- GXJAIOPRPOPJAH-UHFFFAOYSA-N CN1C=NC2=C(Cl)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CN1C=NC2=C(Cl)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 GXJAIOPRPOPJAH-UHFFFAOYSA-N 0.000 description 1
- LEIHLFODGVRBMK-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)CO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)CO)C=C21 LEIHLFODGVRBMK-UHFFFAOYSA-N 0.000 description 1
- PCDIFCAYTFFSCS-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOC(C)(C)CO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOC(C)(C)CO)C=C21 PCDIFCAYTFFSCS-UHFFFAOYSA-N 0.000 description 1
- ZHPAXIQJQFYSCD-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC(C)(C)O)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC(C)(C)O)C=C21 ZHPAXIQJQFYSCD-UHFFFAOYSA-N 0.000 description 1
- HVUPVWYURYMZHF-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC(O)CO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC(O)CO)C=C21 HVUPVWYURYMZHF-UHFFFAOYSA-N 0.000 description 1
- OWJIDNGOXPABQS-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 OWJIDNGOXPABQS-UHFFFAOYSA-N 0.000 description 1
- AZIFGELDXXAIOS-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CCCO3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CCCO3)C=C21 AZIFGELDXXAIOS-UHFFFAOYSA-N 0.000 description 1
- GMNFHSUIRQRMCB-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCC(O)CO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCC(O)CO)C=C21 GMNFHSUIRQRMCB-UHFFFAOYSA-N 0.000 description 1
- ZENGKZDCSVRPRY-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCO)C=C21 ZENGKZDCSVRPRY-UHFFFAOYSA-N 0.000 description 1
- XUMLXFMKTKSYTI-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCOCC3=CC=CC=C3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCOCC3=CC=CC=C3)C=C21 XUMLXFMKTKSYTI-UHFFFAOYSA-N 0.000 description 1
- HZHSPZRUSBUOGX-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCS(=O)(=O)C3=CC=CC=C3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCS(=O)(=O)C3=CC=CC=C3)C=C21 HZHSPZRUSBUOGX-UHFFFAOYSA-N 0.000 description 1
- OXCZQOAOIQLWAC-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCS(C)(=O)=O)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCS(C)(=O)=O)C=C21 OXCZQOAOIQLWAC-UHFFFAOYSA-N 0.000 description 1
- FWIPMAIGLGMRPI-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCSC3=CC=CC=C3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCCSC3=CC=CC=C3)C=C21 FWIPMAIGLGMRPI-UHFFFAOYSA-N 0.000 description 1
- HNPNBTJYUAOAQK-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCN3CCCC3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCN3CCCC3)C=C21 HNPNBTJYUAOAQK-UHFFFAOYSA-N 0.000 description 1
- QUCBKDNJHUAHCH-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCN3CCCCC3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCN3CCCCC3)C=C21 QUCBKDNJHUAHCH-UHFFFAOYSA-N 0.000 description 1
- JJIRSZKUBHKFHU-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCN3CCOCC3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCN3CCOCC3)C=C21 JJIRSZKUBHKFHU-UHFFFAOYSA-N 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- JXFAWTCJJCMHBJ-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCS(=O)(=O)C3=CC=CC=C3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCS(=O)(=O)C3=CC=CC=C3)C=C21 JXFAWTCJJCMHBJ-UHFFFAOYSA-N 0.000 description 1
- JNCSXRLMNDMSSV-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCS(C)(=O)=O)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCS(C)(=O)=O)C=C21 JNCSXRLMNDMSSV-UHFFFAOYSA-N 0.000 description 1
- QQAQCSHSYVUYNU-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCSC3=CC=CC=C3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCSC3=CC=CC=C3)C=C21 QQAQCSHSYVUYNU-UHFFFAOYSA-N 0.000 description 1
- JIKDXMAHCGNIJE-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(O)C3=NC=CC=C3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(O)C3=NC=CC=C3)C=C21 JIKDXMAHCGNIJE-UHFFFAOYSA-N 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C(=O)NOCCO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3F)=C(C(=O)NOCCO)C=C21 ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- UMUZDUWICXBTNI-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 UMUZDUWICXBTNI-UHFFFAOYSA-N 0.000 description 1
- CNSGKPJYNOLBMT-UHFFFAOYSA-N CN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3Cl)=C(C(=O)NOCCO)C=C21 CNSGKPJYNOLBMT-UHFFFAOYSA-N 0.000 description 1
- POADQYHNKIRFRA-UHFFFAOYSA-N CN1CCN(CCCCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)CC1 Chemical compound CN1CCN(CCCCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)CC1 POADQYHNKIRFRA-UHFFFAOYSA-N 0.000 description 1
- DCXNESRBUUAGOV-UHFFFAOYSA-N CN1CCN(CCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)CC1 Chemical compound CN1CCN(CCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)CC1 DCXNESRBUUAGOV-UHFFFAOYSA-N 0.000 description 1
- LQSXITDJUDNRIM-UHFFFAOYSA-N CN1CCN(CCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)CC1 Chemical compound CN1CCN(CCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)CC1 LQSXITDJUDNRIM-UHFFFAOYSA-N 0.000 description 1
- LOYUTTBGUSQZCB-UHFFFAOYSA-N CNCCCCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CNCCCCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 LOYUTTBGUSQZCB-UHFFFAOYSA-N 0.000 description 1
- GIEIWVUEMKYCKK-UHFFFAOYSA-N CNCCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CNCCN1C=NC2=C(F)C(NC3=CC=C(Cl)C=C3C)=C(C(=O)NOCC3CC3)C=C21 GIEIWVUEMKYCKK-UHFFFAOYSA-N 0.000 description 1
- MUTPDZXMZDCKAB-UHFFFAOYSA-N CNCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1.O=C(O)C(F)(F)F Chemical compound CNCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1.O=C(O)C(F)(F)F MUTPDZXMZDCKAB-UHFFFAOYSA-N 0.000 description 1
- TUGMLFCWFNJHSO-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(Br)C=C2C)C(F)=C2N=CN(CCS(C)(=O)=O)C2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(Br)C=C2C)C(F)=C2N=CN(CCS(C)(=O)=O)C2=C1 TUGMLFCWFNJHSO-UHFFFAOYSA-N 0.000 description 1
- VTXHNLBZHPGDKQ-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCN3CCN(C(=O)OC(C)(C)C)CC3)C2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCN3CCN(C(=O)OC(C)(C)C)CC3)C2=C1 VTXHNLBZHPGDKQ-UHFFFAOYSA-N 0.000 description 1
- ZIESFSAFXUGKKA-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCN3CCOCC3)C2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCN3CCOCC3)C2=C1 ZIESFSAFXUGKKA-UHFFFAOYSA-N 0.000 description 1
- UQHKKVOOPYVHAL-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 UQHKKVOOPYVHAL-UHFFFAOYSA-N 0.000 description 1
- CLTQHFHIUIFPMQ-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(Br)C=C2F)C(F)=C2N=CNC2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(Br)C=C2F)C(F)=C2N=CNC2=C1 CLTQHFHIUIFPMQ-UHFFFAOYSA-N 0.000 description 1
- BXWLWMFPQNTOTC-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(Cl)C=C2C)C(F)=C2N=CNC2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(Cl)C=C2C)C(F)=C2N=CNC2=C1 BXWLWMFPQNTOTC-UHFFFAOYSA-N 0.000 description 1
- IAUIXTMHDUCFLO-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(Cl)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(Cl)C=C2Cl)C(F)=C2N=CNC2=C1 IAUIXTMHDUCFLO-UHFFFAOYSA-N 0.000 description 1
- CNPLJAYBCWFZLG-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=C(OC(F)(F)F)C=C2C)C(F)=C2N=CNC2=C1 Chemical compound COC(=O)C1=C(NC2=CC=C(OC(F)(F)F)C=C2C)C(F)=C2N=CNC2=C1 CNPLJAYBCWFZLG-UHFFFAOYSA-N 0.000 description 1
- UXVBXDVPFGJBJT-UHFFFAOYSA-N COC(=O)C1=C(NC2=CC=CC=C2)C(F)=C2N=CNC2=C1 Chemical compound COC(=O)C1=C(NC2=CC=CC=C2)C(F)=C2N=CNC2=C1 UXVBXDVPFGJBJT-UHFFFAOYSA-N 0.000 description 1
- UVCWOHJFUVVZQR-UHFFFAOYSA-N COC1=CC(CN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCCO)C=C32)=CC(OC)=C1 Chemical compound COC1=CC(CN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCCO)C=C32)=CC(OC)=C1 UVCWOHJFUVVZQR-UHFFFAOYSA-N 0.000 description 1
- TYWZTXWVZYCZNW-UHFFFAOYSA-N COCC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound COCC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 TYWZTXWVZYCZNW-UHFFFAOYSA-N 0.000 description 1
- LNPWCHMKQKAWLQ-UHFFFAOYSA-N COCCN1=CNC2=CC(C(=O)NOCC3CC3)=C(NC3=CC=C(Br)C=C3Cl)C(F)=C21 Chemical compound COCCN1=CNC2=CC(C(=O)NOCC3CC3)=C(NC3=CC=C(Br)C=C3Cl)C(F)=C21 LNPWCHMKQKAWLQ-UHFFFAOYSA-N 0.000 description 1
- AYNNWBHLSOIEKQ-UHFFFAOYSA-N COCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound COCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 AYNNWBHLSOIEKQ-UHFFFAOYSA-N 0.000 description 1
- QRRARRUPGYKHOH-UHFFFAOYSA-N COCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound COCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 QRRARRUPGYKHOH-UHFFFAOYSA-N 0.000 description 1
- PFAQWZQBZCLNBR-UHFFFAOYSA-N COCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 Chemical compound COCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 PFAQWZQBZCLNBR-UHFFFAOYSA-N 0.000 description 1
- PNNAMOMAGINWSA-UHFFFAOYSA-N CONC(=O)C1=C(NC2=CC=C(Cl)C=C2C)C(F)=C2N=CNC2=C1 Chemical compound CONC(=O)C1=C(NC2=CC=C(Cl)C=C2C)C(F)=C2N=CNC2=C1 PNNAMOMAGINWSA-UHFFFAOYSA-N 0.000 description 1
- FPLWEYCIDQSXQL-UHFFFAOYSA-N CS(=O)(=O)C1CCN(CCCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)C1 Chemical compound CS(=O)(=O)C1CCN(CCCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)C1 FPLWEYCIDQSXQL-UHFFFAOYSA-N 0.000 description 1
- KEIYPLFFNPAAAY-UHFFFAOYSA-N CS(=O)(=O)C1CCN(CCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)C1 Chemical compound CS(=O)(=O)C1CCN(CCCN2C=NC3=C(F)C(NC4=CC=C(Br)C=C4Cl)=C(C(=O)NOCC4CC4)C=C32)C1 KEIYPLFFNPAAAY-UHFFFAOYSA-N 0.000 description 1
- XLAZRAJXBDPTOS-UHFFFAOYSA-N CS(=O)(=O)CC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound CS(=O)(=O)CC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 XLAZRAJXBDPTOS-UHFFFAOYSA-N 0.000 description 1
- LTMZLFZXNCZFJK-UHFFFAOYSA-N CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NN)C=C21 Chemical compound CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NN)C=C21 LTMZLFZXNCZFJK-UHFFFAOYSA-N 0.000 description 1
- QQQSYBHSICNYPZ-UHFFFAOYSA-N CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 QQQSYBHSICNYPZ-UHFFFAOYSA-N 0.000 description 1
- FCPYUFOCGFDWNV-UHFFFAOYSA-N CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 Chemical compound CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21 FCPYUFOCGFDWNV-UHFFFAOYSA-N 0.000 description 1
- CUBLJZPTERGPFD-UHFFFAOYSA-N CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)O)C=C21 Chemical compound CS(=O)(=O)CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)O)C=C21 CUBLJZPTERGPFD-UHFFFAOYSA-N 0.000 description 1
- KEYURTLIEYKWPE-UHFFFAOYSA-N CSCCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 Chemical compound CSCCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 KEYURTLIEYKWPE-UHFFFAOYSA-N 0.000 description 1
- WAQMADQIOCFJRY-UHFFFAOYSA-N CSCCON Chemical compound CSCCON WAQMADQIOCFJRY-UHFFFAOYSA-N 0.000 description 1
- PDYSFRDDNJVLAN-UHFFFAOYSA-N CSCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 Chemical compound CSCCONC(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(C)C2=C1 PDYSFRDDNJVLAN-UHFFFAOYSA-N 0.000 description 1
- FZPXSAZGFRCCEX-UHFFFAOYSA-N FC1=C2N=CNC2=CC(C2=CN=CN2)=C1NC1=CC=C(Br)C=C1Cl Chemical compound FC1=C2N=CNC2=CC(C2=CN=CN2)=C1NC1=CC=C(Br)C=C1Cl FZPXSAZGFRCCEX-UHFFFAOYSA-N 0.000 description 1
- TYRDWYZZGDZJBO-UHFFFAOYSA-N FC1=C2N=CNC2=CC(C2=CN=CO2)=C1NC1=CC=C(Br)C=C1Cl Chemical compound FC1=C2N=CNC2=CC(C2=CN=CO2)=C1NC1=CC=C(Br)C=C1Cl TYRDWYZZGDZJBO-UHFFFAOYSA-N 0.000 description 1
- QZHDMNSWICMYCO-UHFFFAOYSA-N N#CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 Chemical compound N#CCCCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21 QZHDMNSWICMYCO-UHFFFAOYSA-N 0.000 description 1
- SKZJMQKTNVILJI-UHFFFAOYSA-N NC1=NN=C(C2=C(NC3=CC=C(Br)C=C3Cl)C(F)=C3N=CNC3=C2)O1 Chemical compound NC1=NN=C(C2=C(NC3=CC=C(Br)C=C3Cl)C(F)=C3N=CNC3=C2)O1 SKZJMQKTNVILJI-UHFFFAOYSA-N 0.000 description 1
- MZBKMHQRPFGWSJ-UHFFFAOYSA-N NOCCCSc1ccccc1 Chemical compound NOCCCSc1ccccc1 MZBKMHQRPFGWSJ-UHFFFAOYSA-N 0.000 description 1
- PYXHZSPWJIANNK-UHFFFAOYSA-N NOCCN1CCCC1 Chemical compound NOCCN1CCCC1 PYXHZSPWJIANNK-UHFFFAOYSA-N 0.000 description 1
- YOUVHXQKCSEVSP-UHFFFAOYSA-N NOCCN1CCCCC1 Chemical compound NOCCN1CCCCC1 YOUVHXQKCSEVSP-UHFFFAOYSA-N 0.000 description 1
- SNOUISOFFNFLTM-UHFFFAOYSA-N NOCCSC1=CC=CC=C1 Chemical compound NOCCSC1=CC=CC=C1 SNOUISOFFNFLTM-UHFFFAOYSA-N 0.000 description 1
- UEASYHPABYVXRN-UHFFFAOYSA-N O=C(CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21)NCC1=NC=CC=C1 Chemical compound O=C(CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCC3CC3)C=C21)NCC1=NC=CC=C1 UEASYHPABYVXRN-UHFFFAOYSA-N 0.000 description 1
- DLJACZXPCYRJSO-UHFFFAOYSA-N O=C(CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21)NCC1=NC=CC=C1 Chemical compound O=C(CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3Cl)=C(C(=O)NOCCO)C=C21)NCC1=NC=CC=C1 DLJACZXPCYRJSO-UHFFFAOYSA-N 0.000 description 1
- CAXHDHWFHGXNKM-UHFFFAOYSA-N O=C(CO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound O=C(CO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 CAXHDHWFHGXNKM-UHFFFAOYSA-N 0.000 description 1
- GCJGNFWTQMIEJR-UHFFFAOYSA-N O=C(NC1=NC=CS1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound O=C(NC1=NC=CS1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 GCJGNFWTQMIEJR-UHFFFAOYSA-N 0.000 description 1
- LAHHWNRLGBYUJA-UHFFFAOYSA-N O=C(NC1=NN=NN1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound O=C(NC1=NN=NN1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 LAHHWNRLGBYUJA-UHFFFAOYSA-N 0.000 description 1
- QANCAGDEDHSHPQ-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCN3CCNCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC#CCN3CCNCC3)C2=C1 QANCAGDEDHSHPQ-UHFFFAOYSA-N 0.000 description 1
- JKOGDWJJDDVHGY-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC(=O)N3CCCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC(=O)N3CCCC3)C2=C1 JKOGDWJJDDVHGY-UHFFFAOYSA-N 0.000 description 1
- XAMZDUQWTOWCMI-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC3OCCO3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC3OCCO3)C2=C1 XAMZDUQWTOWCMI-UHFFFAOYSA-N 0.000 description 1
- PMWGMSJPZVJJNA-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCCCl)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCCCl)C2=C1 PMWGMSJPZVJJNA-UHFFFAOYSA-N 0.000 description 1
- XALWYJKGWFJMKZ-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCCN3CCOCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCCN3CCOCC3)C2=C1 XALWYJKGWFJMKZ-UHFFFAOYSA-N 0.000 description 1
- AVWSCXGZERIBOZ-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCCl)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCCl)C2=C1 AVWSCXGZERIBOZ-UHFFFAOYSA-N 0.000 description 1
- MPLQMVSPWJMYNY-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3C=CN=C3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3C=CN=C3)C2=C1 MPLQMVSPWJMYNY-UHFFFAOYSA-N 0.000 description 1
- RYUSCOJRKSCERV-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCC(O)C3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCC(O)C3)C2=C1 RYUSCOJRKSCERV-UHFFFAOYSA-N 0.000 description 1
- WFPMDUKXKVIABG-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCN(C4=CC=NC=C4)CC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCN(C4=CC=NC=C4)CC3)C2=C1 WFPMDUKXKVIABG-UHFFFAOYSA-N 0.000 description 1
- BCDXIDLMYYXXIR-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCNCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCNCC3)C2=C1 BCDXIDLMYYXXIR-UHFFFAOYSA-N 0.000 description 1
- JMIRMPFEZDOOSS-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCOCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCOCC3)C2=C1 JMIRMPFEZDOOSS-UHFFFAOYSA-N 0.000 description 1
- HBNKTYLINRGZQD-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCNC3=NC=CS3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCNC3=NC=CS3)C2=C1 HBNKTYLINRGZQD-UHFFFAOYSA-N 0.000 description 1
- RDXNHPYFZXDPCQ-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCO)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCO)C2=C1 RDXNHPYFZXDPCQ-UHFFFAOYSA-N 0.000 description 1
- NWDRJWCEKYYNNO-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCl)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCl)C2=C1 NWDRJWCEKYYNNO-UHFFFAOYSA-N 0.000 description 1
- SRKVQZTVAXWXPX-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3C=CN=C3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3C=CN=C3)C2=C1 SRKVQZTVAXWXPX-UHFFFAOYSA-N 0.000 description 1
- KEEHHMZCEQDFMA-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3CCC(O)C3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3CCC(O)C3)C2=C1 KEEHHMZCEQDFMA-UHFFFAOYSA-N 0.000 description 1
- VAAXOIUZYZDIPK-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3CCN(C4=CC=NC=C4)CC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3CCN(C4=CC=NC=C4)CC3)C2=C1 VAAXOIUZYZDIPK-UHFFFAOYSA-N 0.000 description 1
- HUIGPWVHWOHHAQ-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3CCNCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCN3CCNCC3)C2=C1 HUIGPWVHWOHHAQ-UHFFFAOYSA-N 0.000 description 1
- VWGXFLFBDZQDCK-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCNC3=NC=CS3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCNC3=NC=CS3)C2=C1 VWGXFLFBDZQDCK-UHFFFAOYSA-N 0.000 description 1
- DODNKKBJUHANCQ-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCO)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCO)C2=C1 DODNKKBJUHANCQ-UHFFFAOYSA-N 0.000 description 1
- VUSHSWATQXFMGE-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCl)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCl)C2=C1 VUSHSWATQXFMGE-UHFFFAOYSA-N 0.000 description 1
- FQNKIZFNOZMCEW-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCN3C=CN=C3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCN3C=CN=C3)C2=C1 FQNKIZFNOZMCEW-UHFFFAOYSA-N 0.000 description 1
- ZXAZMAGVUSRKBT-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCN3CCC(O)C3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCN3CCC(O)C3)C2=C1 ZXAZMAGVUSRKBT-UHFFFAOYSA-N 0.000 description 1
- VOJDGRCRCRNGLD-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCN3CCOCC3)C2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCN3CCOCC3)C2=C1 VOJDGRCRCRNGLD-UHFFFAOYSA-N 0.000 description 1
- KHNUMHAPGZJGJD-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 KHNUMHAPGZJGJD-UHFFFAOYSA-N 0.000 description 1
- UUOFVWGJTYGGTJ-UHFFFAOYSA-N O=C(NOCC1CC1)C1=C(NC2=CC=C(Cl)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound O=C(NOCC1CC1)C1=C(NC2=CC=C(Cl)C=C2Cl)C(F)=C2N=CNC2=C1 UUOFVWGJTYGGTJ-UHFFFAOYSA-N 0.000 description 1
- OJONGCVODOVJFH-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(Cl)=C2N=CNC2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(Cl)=C2N=CNC2=C1 OJONGCVODOVJFH-UHFFFAOYSA-N 0.000 description 1
- XBQJXQIWHVYNJC-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC(F)(F)F)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC(F)(F)F)C2=C1 XBQJXQIWHVYNJC-UHFFFAOYSA-N 0.000 description 1
- DYFMFQDMVSMKNB-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3=CC=C(Cl)C=C3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3=CC=C(Cl)C=C3)C2=C1 DYFMFQDMVSMKNB-UHFFFAOYSA-N 0.000 description 1
- INGIFPKCSHEVDQ-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3=CC=C(F)C=C3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3=CC=C(F)C=C3)C2=C1 INGIFPKCSHEVDQ-UHFFFAOYSA-N 0.000 description 1
- QBOLOVBUXFHNLB-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3=CC=CC=C3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3=CC=CC=C3)C2=C1 QBOLOVBUXFHNLB-UHFFFAOYSA-N 0.000 description 1
- DDZVWOPAQZGCEE-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3=CC=CC=N3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3=CC=CC=N3)C2=C1 DDZVWOPAQZGCEE-UHFFFAOYSA-N 0.000 description 1
- CMEHLCHISZOAFE-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CC3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CC3)C2=C1 CMEHLCHISZOAFE-UHFFFAOYSA-N 0.000 description 1
- NNYZAXMEFLDKAK-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCC3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCC3)C2=C1 NNYZAXMEFLDKAK-UHFFFAOYSA-N 0.000 description 1
- QCYWEIJRRQDOMB-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCCCC3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCCCC3)C2=C1 QCYWEIJRRQDOMB-UHFFFAOYSA-N 0.000 description 1
- MEDYRLZHKMRQBE-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCCCO3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCCCO3)C2=C1 MEDYRLZHKMRQBE-UHFFFAOYSA-N 0.000 description 1
- JVPMEEQIGAMTTE-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCCO3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCCO3)C2=C1 JVPMEEQIGAMTTE-UHFFFAOYSA-N 0.000 description 1
- MPYLKODCOMIMAR-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCNCC3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCNCC3)C2=C1 MPYLKODCOMIMAR-UHFFFAOYSA-N 0.000 description 1
- MHQPLYHTDRDAPW-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCOCC3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CC3CCOCC3)C2=C1 MHQPLYHTDRDAPW-UHFFFAOYSA-N 0.000 description 1
- QMEGMPKFELJNHZ-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC(=O)N3CCCC3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC(=O)N3CCCC3)C2=C1 QMEGMPKFELJNHZ-UHFFFAOYSA-N 0.000 description 1
- DKOAOBPTKOPWTI-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC(O)CO)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC(O)CO)C2=C1 DKOAOBPTKOPWTI-UHFFFAOYSA-N 0.000 description 1
- CYEUOBXGIYRESI-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC3CCCCC3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCC3CCCCC3)C2=C1 CYEUOBXGIYRESI-UHFFFAOYSA-N 0.000 description 1
- MAWCZTNOCKHPRH-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCOCC3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCN3CCOCC3)C2=C1 MAWCZTNOCKHPRH-UHFFFAOYSA-N 0.000 description 1
- BXIUVZFTUFHEPY-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCO)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CN(CCCCO)C2=C1 BXIUVZFTUFHEPY-UHFFFAOYSA-N 0.000 description 1
- PMDQQHJJZRFUAL-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2F)C(F)=C2N=CN(CC3CCCCO3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Br)C=C2F)C(F)=C2N=CN(CC3CCCCO3)C2=C1 PMDQQHJJZRFUAL-UHFFFAOYSA-N 0.000 description 1
- HMTXHEBCRSVBFA-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Cl)C=C2Cl)C(F)=C2N=CN(CC3CCCCO3)C2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Cl)C=C2Cl)C(F)=C2N=CN(CC3CCCCO3)C2=C1 HMTXHEBCRSVBFA-UHFFFAOYSA-N 0.000 description 1
- LIVKEAHZXNTRIX-UHFFFAOYSA-N O=C(NOCCO)C1=C(NC2=CC=C(Cl)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound O=C(NOCCO)C1=C(NC2=CC=C(Cl)C=C2Cl)C(F)=C2N=CNC2=C1 LIVKEAHZXNTRIX-UHFFFAOYSA-N 0.000 description 1
- ZBLGZIIFSWSWKZ-UHFFFAOYSA-N OCC(O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound OCC(O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 ZBLGZIIFSWSWKZ-UHFFFAOYSA-N 0.000 description 1
- FHAVWVCECJAGMW-UHFFFAOYSA-N OCC1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound OCC1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 FHAVWVCECJAGMW-UHFFFAOYSA-N 0.000 description 1
- JGEHBMBUGXBXAU-UHFFFAOYSA-N [C-]#[N+]CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)NOCC3CC3)C=C21 Chemical compound [C-]#[N+]CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)NOCC3CC3)C=C21 JGEHBMBUGXBXAU-UHFFFAOYSA-N 0.000 description 1
- UGAZKWLJWQBTAO-UHFFFAOYSA-N [C-]#[N+]CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)OC)C=C21 Chemical compound [C-]#[N+]CCN1C=NC2=C(F)C(NC3=CC=C(Br)C=C3C)=C(C(=O)OC)C=C21 UGAZKWLJWQBTAO-UHFFFAOYSA-N 0.000 description 1
- YPZABVLTKBFEOE-UHFFFAOYSA-N [H]C(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 Chemical compound [H]C(=O)C1=C(NC2=CC=C(Br)C=C2Cl)C(F)=C2N=CNC2=C1 YPZABVLTKBFEOE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to a series of alkylated (1H-Benzoimidazol-5-yl)-(4-substituted-phenyl)-amine derivatives that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals.
- This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
- MAP kinase pathways are important regulator of cell growth, proliferation and differentiation.
- growth factors through receptor activation (i.e. PDGF or EGF and others), activate MAP kinase pathways.
- PDGF receptor activation
- MAP kinase pathways One of the most important and most well understood MAP kinase pathways involved in normal and uncontrolled cell growth is the Ras/Raf kinase pathway. Active GTP-bound Ras results in the activation and indirect phosphorylation of Raf kinase.
- Raf then phosphorylates MEB1 and 2 on two serine residues (S218 and S222 for MEK1 and S222 and S226 for MEK2) (Ahn et al., Methods in Enzymology 2001, 332, 417-431).
- Activated MEK then phosphorylates its only known substrates, the MAP kinases, ERK1 and 2.
- ERK phosphorylation by MEK occurs on Y204 and T202 for ERK1 and Y185 and T183 for ERK2 (Ahn et al., Methods in Enzymology 2001, 332, 417-431).
- ERK Phosphorylated ERK dimerizes and then translocates to the nucleus where it accumulates (Khokhlatchev et al., Cell 1998, 93, 605-615). In the nucleus, ERK is involved in several important cellular functions, including but not limited to nuclear transport, signal transduction, DNA repair, nucleosome assembly and translocation, and mRNA processing and translation (Ahn et al., Molecular Cell 2000, 6, 1343-1354). Overall, treatment of cells with growth factors leads to the activation of ERK1 and 2 which results in proliferation and, in some cases, differentiation (Lewis et al., Adv. Cancer Res. 1998, 74, 49-139).
- bRaf mutations have been identified in more than 60% of malignant melanoma (Davies, H. et al., Nature 2002, 417, 949-954). These mutations in bRaf result in a constitutively active MAP kinase cascade. Studies of primary tumor samples and cell lines have also shown constitutive or overactivation of the MAP kinase pathway in cancers of pancreas, colon, lung, ovary and kidney (Hoshino, R. et al., Oncogene 1999, 18, 813-822). Hence, there is a strong correlation between cancers and an overactive MAP kinase pathway resulting from genetic mutations.
- MEK is a key player in this pathway as it is downstream of Ras and Raf. Additionally, it is an attractive therapeutic target because the only known substrates for MEK phosphorylation are the MAP kinases, ERK1 and 2. Inhibition of MEK has been shown to have potential therapeutic benefit in several studies.
- small molecule MEK inhibitors have been shown to inhibit human tumor growth in nude mouse xenografts, (Sebolt-Leopold et al., Nature - Medicine 1999, 5 (7), 810-816; Trachet et al., AACR Apr. 6-10, 2002, Poster #5426; Tecle, H. IBC 2 nd International Conference of Protein Kinases, Sep. 9-10, 2002), block static allodynia in animals (WO 01/05390 published Jan. 25, 2001) and inhibit growth of acute myeloid leukemia cells (Milella et al., J Clin Invest 2001, 108 (6), 851-859).
- This invention provides for alkylated (1H-benzoimidazol-5-yl)-(4-substituted phenyl)-amine compounds of formula I, and pharmaceutically acceptable salts and prodrugs thereof that are useful in the treatment of hyperproliferative diseases.
- the present invention relates to compounds of formula I that act as MEK inhibitors.
- a method for treatment of cancer Also provided are formulations containing compounds of formula I and methods of using the compounds to treat a patient in need thereof.
- R 1 , R 2 , R 9 and R 10 are independently selected from hydrogen, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —OR 3 , —C(O)R 3 , —C(O)OR 3 , NR 4 C(O)OR 6 , —OC(O)R 3 , —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , —NR 3 R 4 , and
- R 3 is selected from hydrogen, trifluoromethyl, and
- R′, R′′ and R′′′ independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl;
- R′′′′ is selected from lower alkyl, lower alkenyl, aryl and arylalkyl; or
- R′, R′′, R′′′ or R′′′′ can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or
- R 3 and R 4 can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR′SO 2 R′′′′, —SO 2 NR′R′′, —C(O)R′, —C(O)OR′, —OC(O)R′, —NR′C(O)OR′′′′, —NR′C(O)R′′, —C(O)NR′R′′, —SO 2 R′′′′, —NR′R′′, —NR′C(O)NR′′R′′′, —NR′C(NCN)NR′′R′′′, —OR′, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl,
- R 4 and R 5 independently represent hydrogen or C 1 -C 6 alkyl
- R 4 and R 5 together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR′SO 2 R′′′′, —SO 2 NR′R′′, —C(O)R′′′′, —C(O)OR′, —OC(O)R′, —NR′C(O)OR′′′′, —NR′C(O)R′′, —C(O)NR′R′′, —SO 2 R′′′′, —NR′R′′, —NR′C(O)NR′′R′′′, —NR′C(NCN)NR′′R′′′, —OR′, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocycl
- R 6 is selected from trifluoromethyl
- R 7 is selected from hydrogen
- W is selected from heteroaryl, heterocyclyl, —C(O)OR 3 , —C(O)NR 3 R 4 , —C(O)NR 4 OR 3 , —C(O)R 4 OR 3 , —C(O)(C 3 -C 10 cycloalkyl), —C(O)(C 1 -C 10 alkyl), —C(O)(aryl), —C(O)(heteroaryl) and —C(O)(heterocyclyl), each of which is optionally substituted with 1-5 groups independently selected from
- R 8 is selected from hydrogen, —SCF 3 , —Cl, —Br, —F, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —OR 3 , —C(O)R 3 , —C(O)OR 3 , —NR 4 C(O)OR 6 , —OC(O)R 3 , —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 3 R 4 , and
- m is 0, 1, 2, 3, 4 or 5;
- j is 1 or 2.
- novel compounds encompassed by the instant invention are those described by the general formula I set forth above, and the pharmaceutically acceptable salts and prodrugs thereof.
- R 7 is C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkylalkyl, C 3 -C 7 heterocycloalkyl or C 3 -C 7 heterocycloalkylalkyl each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —C(O)R 3 , —C(O)OR 3 , —OC(O)R 3 , —SO 2 R 3 , —NR 4 C(O)OR 6 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 C(O)NR 3 R
- the present invention also provides compounds of formula I wherein R 8 is —OCF 3 , —Br or —Cl, R 2 is hydrogen, and R 1 is lower alkyl or halogen.
- the present invention also provides compounds of formula I wherein R 9 is hydrogen or halogen, and R 10 is hydrogen.
- the present invention also provides compounds of formula I wherein W is —C(O)OR 3 or —C(O)NR 4 OR 3 .
- R 7 is C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl or C 3 -C 7 cycloalkylalkyl, each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —C(O)R 3 , —C(O)OR 3 , —OC(O)R 3 , —SO 2 R 3 , —NR 4 C(O)OR 6 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , —OR 3 , aryl,
- the present invention also provides compounds of formula II wherein R 8 is —OCF 3 , —Br or —Cl, and R 1 is lower alkyl or halogen.
- the present invention also provides compounds of formula II wherein R 9 is hydrogen or halogen, and R 10 is hydrogen.
- the present invention also provides compounds of formula II wherein W is —C(O)OR 3 or —C(O)NR 4 OR 3 .
- R 1 , R 2 , R 7 , R 8 and R 9 are as defined above for formula I, and A is —OR 3 or —NR 4 OR 3 , wherein R 3 and R 4 are as defined above for formula I.
- R 7 is C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl or C 3 -C 7 cycloalkylalkyl, each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —C(O)R 3 , —C(O)OR 3 , —OC(O)R 3 , —SO 2 R 3 , —NR 4 C(O)OR 6 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , —OR 3 , aryl,
- the present invention also provides compounds of formula III wherein R 8 is —OCF 3 , —Br or —Cl, R 2 is hydrogen, and R 1 is lower alkyl or halogen.
- the present invention also provides compounds of formula III wherein R 9 is hydrogen or halogen.
- the present invention also provides compounds of formula III wherein R 3 is hydrogen or lower alkyl when A is —OR 3 ; and R 4 is hydrogen when A is —NR 4 OR 3 .
- R 1 , R 2 , R 7 , R 8 and R 9 are as defined above for formula I, and A is —OR 3 or —NR 4 OR 3 , wherein R 3 and R 4 are as defined above for formula I.
- R 7 is C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl or C 3 -C 7 cycloalkylalkyl, each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —C(O)R 3 , —C(O)OR 3 , —OC(O)R 3 , —SO 2 R 3 , —NR 4 C(O)OR 6 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , —OR 3 , aryl
- the present invention also provides compounds of formula IIIa wherein R 8 is —OCF 3 , —Br or —Cl, R 2 is hydrogen, and R 1 is lower alkyl or halogen.
- the present invention also provides compounds of formula IIIa wherein R 9 is hydrogen or halogen.
- the present invention also provides compounds of formula IIIa wherein R 3 is hydrogen or lower alkyl when A is —OR 3 ; and R 4 is hydrogen when A is —NR 4 OR 3 .
- R 7 , R 7 , R 8 and R 9 are as defined above for formula I
- A is —OR 3 or —NR 4 OR 3 , wherein R 3 and R 4 are as defined above for formula I.
- R 7 is C 1 -C 10 alkyl, C 3 -C 7 cycloalkyl or C 3 -C 7 cycloalkylalkyl, each of which can be optionally substituted with 1-3 groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, —NR 4 SO 2 R 6 , —SO 2 NR 3 R 4 , —C(O)R 3 , —C(O)OR 3 , —OC(O)R 3 , —SO 2 R 3 , —NR 4 C(O)OR 6 , —NR 4 C(O)R 3 , —C(O)NR 3 R 4 , —NR 3 R 4 , —NR 5 C(O)NR 3 R 4 , —NR 5 C(NCN)NR 3 R 4 , —OR 3 , aryl
- the present invention also provides compounds of formula IIIb wherein R 8 is —OCF 3 , —Br or —Cl, and R 1 is lower alkyl or halogen.
- the present invention also provides compounds of formula IIIb wherein R 9 is fluoro or chloro.
- the present invention also provides compounds of formula IIIb wherein R 3 is hydrogen or lower alkyl when A is —OR 3 ; and R 4 is hydrogen when A is —NR 4 OR 3 .
- C 1 -C 10 alkyl straight or branched chain alkyl groups having 1-10 carbon atoms, such as, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, heptyl, octyl, and the like.
- Preferred alkyl radicals are C 1-6 alkyl. More preferred alkyl radicals are C 1-3 alkyl.
- C 2 -C 10 alkenyl means straight and branched hydrocarbon radicals having from 2 to 10 carbon atoms and at least one double bond and includes ethenyl, propenyl, 1-but-3-enyl, 1-pent-3-enyl, 1-hex-5-enyl and the like. More preferred are lower alkenyl having 3-5 carbon atoms.
- C 2 -C 10 alkynyl means straight and branched hydrocarbon radicals having from 2 to 10 carbon atoms and at least one triple bond and includes ethynyl, propynyl, butynyl, pentyn-2-yl and the like. More preferred are alkynyl having 3-5 carbon atoms.
- halogen in the present invention is meant fluorine, bromine, chlorine, and iodine.
- aryl is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl), which is optionally mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, trifluoromethyl, aryl, heteroaryl, and hydroxy.
- heteroaryl is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings which includes fused ring systems (at least one of which is aromatic) of 5-10 atoms containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur.
- heteroaryl groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl,
- Heteroaryl groups are optionally mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, haloalkyl, aryl, heteroaryl, and hydroxy.
- the term “carbocycle”, “carbocyclyl”, “cycloalkyl” or “C 3 -C 10 cycloalkyl” refers to saturated carbocyclic radicals having three to ten carbon atoms.
- the cycloalkyl can be monocyclic, or a polycyclic fused system, and can be fused to an aromatic ring. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- the cycloalkyl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups.
- such cycloalkyl groups may be optionally substituted with, for example, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C 1 -C 6 )alkylamino, di(C 1 -C 6 )alkylamino, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, amino(C 1 -C 6 )alkyl, mono(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl or di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl.
- heterocycle or “heterocyclyl” is meant one or more carbocyclic ring systems of 5-, 6-, or 7-membered rings which includes fused ring systems of 4-10 atoms containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur, and with the proviso that the ring of the group does not contain two adjacent O or S atoms.
- a fused system can be a heterocycle fused to an aromatic group.
- Preferred heterocycles include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl,
- Spiro moieties are also included within the scope of this definition.
- the foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible.
- a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
- a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).
- An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo ( ⁇ O) moieties is 1,1-dioxo-thiomorpholinyl.
- heterocycle groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups.
- such heterocycle groups may be optionally substituted with, for example, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, hydroxy, cyano, nitro, amino, mono(C 1 -C 6 )alkylamino, di(C 1 -C 6 )alkylamino, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, amino(C 1 -C 6 )alkyl, mono(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl or di(C 1 -C 6 )alkylamino(C 1 -C 6 )alkyl.
- arylalkyl means an alkyl moiety (as defined above) substituted with one or more aryl moiety (also as defined above). More preferred arylalkyl radicals are aryl-C 1-3 -alkyls. Examples include benzyl, phenylethyl, and the like.
- heteroarylalkyl means an alkyl moiety (as defined above) substituted with a heteroaryl moiety (also as defined above). More preferred heteroarylalkyl radicals are 5- or 6-membered heteroaryl-C 1-3 -alkyls. Examples include, oxazolylmethyl, pyridylethyl and the like.
- heterocyclylalkyl means an alkyl moiety (as defined above) substituted with a heterocyclyl moiety (also defined above). More preferred heterocyclylalkyl radicals are 5- or 6-membered heterocyclyl-C 1-3 -alkyls. Examples include tetrahydropyranylmethyl.
- cycloalkylalkyl means an alkyl moiety (as defined above) substituted with a cycloalkyl moiety (also defined above). More preferred heterocyclyl radicals are 5- or 6-membered cycloalkyl-C 1-3 -alkyls. Examples include cyclopropylmethyl.
- Me means methyl
- Et means ethyl
- Bu means butyl
- Ac means acetyl
- phrases “pharmaceutically acceptable salt(s)”, as used herein, unless otherwise indicated, includes salts of acidic and basic groups which may be present in the compounds of the present invention.
- the compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
- acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of the present invention are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate,
- a salt may be formed by treatment of a compound of the present invention with a basic compound, particularly an inorganic base.
- Preferred inorganic salts are those formed with alkali and alkaline earth metals such as lithium, sodium, potassium, barium and calcium.
- Preferred organic base salts include, for example, ammonium, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylamine, dibenzyl-ethylenediamine, and the like salts.
- salts of acidic moieties may include, for example, those salts formed with procaine, quinine and N-methylglusoamine, plus salts formed with basic amino acids such as glycine, ornithine, histidine, phenylglycine, lysine and arginine.
- An especially preferred salt is a sodium or potassium salt of a compound of the present invention.
- a salt is formed by the treatment of a compound of the present invention with an acidic compound, particularly an inorganic acid.
- Preferred inorganic salts of this type may include, for example, the hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric or the like salts.
- Preferred organic salts of this type may include, for example, salts formed with formic, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, glycolic, phthalic, tartaric, lauric, stearic, salicyclic, methanesulfonic, benzenesulfonic, paratoluenesulfonic, sorbic, puric, benzoic, cinnamic and the like organic acids.
- An especially preferred salt of this type is a hydrochloride or sulfate salt of a compound of the present invention.
- R 4 and R 5 may vary with each iteration of m or t above 1.
- R 4 and R 5 may equal —CH 2 CH 2 — or —CH(CH 3 )C(CH 2 CH 3 )(CH 2 CH 2 CH 3 )— or any number of similar moieties falling within the scope of the definitions of R 4 and R 5 .
- Certain compounds of the present invention may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, are considered to be within the scope of the invention. With respect to the compounds of the present invention, the invention includes the use of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, or mixtures thereof. The compounds of the present invention may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof.
- the subject invention also includes isotopically-labeled compounds, which are identical to those recited in the present invention, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chloride, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
- isotopically labeled compound of the present invention and prodrugs thereof can generally be prepared by carrying out procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
- This invention also encompasses pharmaceutical compositions containing a compound of formulas I-IIIb and methods of treating proliferative disorders, or abnormal cell growth, by administering prodrugs of compounds of the the present invention.
- Compounds of the present invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs.
- Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the present invention.
- the amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvaline, beta-alanine, ganuna-aminobutyric acid, cirtulline, homocysteine, homoserine, omithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters.
- Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews 1996, 19, 115.
- Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups.
- acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed.
- Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
- radical arylalkyl is attached to the structure in question by the alkyl group.
- the invention also relates to a pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
- said pharmaceutical composition is for the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer.
- said pharmaceutical composition is for the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g.,benign prostatic hypertrophy (BPH)).
- a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g.,benign prostatic hypertrophy (BPH)).
- the invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced renal disease) or the treatment of pain in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
- the invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
- the invention also relates to a pharmaceutical composition for treating a disease related to vasculogenesis or angiogenesis in a mammal which comprises a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
- said pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
- a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma,
- the invention also relates to a method of treating a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
- said method relates to the treatment of cancer such as brain, lung, squamous cell, bladder, gastic, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, esophageal, testicular, gynecological or thyroid cancer.
- said method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g.,benign prostatic hypertrophy (BPH)).
- a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g.,benign prostatic hypertrophy (BPH)).
- the invention also relates to a method for the treatment of a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
- an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
- the invention also relates to a method of treating pancreatitis or kidney disease in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
- the invention also relates to a method of preventing blastocyte implantation in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
- the invention also relates to a method of treating diseases related to vasculogenesis or angiogenesis in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
- said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
- a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma,
- Patients that can be treated with compounds of the present invention, or pharmaceutically acceptable salts, prodrugs and hydrates of said compounds, according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, restenosis, atherosclerosis, BPH, lung cancer, bone cancer, CMML, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, testicular, gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e.g., cancer of the thyroid, parathyroid or
- This invention also relates to a pharmaceutical composition for inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with an amount of a chemotherapeutic, wherein the amounts of the compound, salt, solvate, or prodrug, and of the chemotherapeutic are together effective in inhibiting abnormal cell growth.
- chemotherapeutics are presently known in the art.
- the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
- This invention further relates to a method for inhibiting abnormal cell growth in a mammal or treating a hyperproliferative disorder which method comprises administering to the mammal an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with radiation therapy, wherein the amounts of the compound, salt, solvate, or prodrug, is in combination with the radiation therapy effective in inhibiting abnormal cell growth or treating the hyperproliferative disorder in the mammal.
- Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein.
- the administration of the compound of the invention in this combination therapy can be determined as described herein.
- this invention further relates to a method for sensitizing abnormal cells in a mammal to treatment with radiation which comprises administering to the mammal an amount of a compound of the present invention or pharmaceutically acceptable salt or solvate or prodrug thereof, which amount is effective is sensitizing abnormal cells to treatment with radiation.
- the amount of the compound, salt, or solvate in this method can be determined according to the means for ascertaining effective amounts of such compounds described herein.
- the invention also relates to a method of and to a pharmaceutical composition of inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of the present invention, or a pharmaceutically acceptable salt or solvate thereof, a prodrug thereof, or an isotopically-labeled derivative thereof, and an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents.
- Anti-angiogenesis agents such as MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors, can be used in conjunction with a compound of the present invention and pharmaceutical compositions described herein.
- MMP-2 matrix-metalloprotienase 2
- MMP-9 matrix-metalloprotienase 9 inhibitors
- COX-II cyclooxygenase II
- Examples of useful COX-II inhibitors include CELEBREXTM (alecoxib), valdecoxib, and rofecoxib.
- Examples of useful matrix metalloprotienase inhibitors are described in WO 96/33172 (published Oct. 24, 1996), WO 96/27583 (published Mar. 7, 1996), European Patent Application No.
- MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e., MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).
- MMP-1, MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13 matrix-metalloproteinases
- MMP inhibitors useful in the present invention are AG-3340, RO 32-3555, and RS 13-0830.
- abnormal cell growth and “hyperproliferative disorder” are used interchangeably in this application.
- abnormal cell growth refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes, for example, the abnormal growth of: (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (3) any tumors that proliferate by receptor tyrosine kinases; (4) any tumors that proliferate by aberrant serine/threonine kinase activation; and (5) benign and malignant cells of other proliferative diseases in which aberrant serine/theroine kinase activation occurs.
- treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
- treatment refers to the act of treating as “treating” is defined immediately above.
- Representative compounds of the present invention include, but are not limited to the compounds of the examples and their pharmaceutically acceptable acid or base addition salts or prodrugs thereof.
- Scheme 1 illustrates the synthesis of compounds of the present invention.
- the acid is nitrated using standard conditions preferable fuming nitric acid in H 2 SO 4 .
- the aniline is prepared by fluoride displacement with NH 4 OH at room temperature in water followed by careful acidification with concentrated mineral acid to pH near 0.
- the ester is prepared by standard methods including by not limited to Fisher Esterification (MeOH, H 2 SO 4 ), and reaction with TMSCHN 2 in suitable organic solvents like PhMe/MeOH or THF/MeOH.
- the dianilino derivative is prepared by heating (60 to 200° C.) the ester with an excess of the appropriate aniline neat or in an organic solvent like xylenes.
- step 5 the preferred method is stirring the ester with 10 equivalents aniline in xylenes at reflux until complete reaction.
- the nitro arene is reduced to produce the diamine by standard reduction conditions, including by not limited to H 2 , and Pd/C or Pd(OH) 2 /C or Raney Nickel in organic solvent like EtOH or THF, Fe in AcOH, Zn in AcOH or Zn, NH 4 Cl (aq) in MeOH.
- step 6 the diamine is cyclization by heating with formic acid neat or formamidine acetate in an appropriate solvent like EtOH.
- the nitro arene can be converted directly to the benzimidazole in step 7 by heating in formic acid with Pd(OH) 2 /C or other palladium source like Pd/C.
- a halide can be incorporated by standard methods, including but not limited to NBS or NCS and pTsOH in organic cosolvents like THF and MeOH.
- the benzimidazole is alkylated to give a near equal mixture of N1 and N3 products which are separable by standard techniques, including, for example, chromatography and trituration.
- the alkylation is accomplished by use of an alkylating agent like an alkyl halide and base like NaH, or K 2 CO 3 in suitable organic solvent like DMF or THF at temperatures ranging from 0 to 80° C.
- R 7 can be further modified by various synthetic methods known in the art, as exemplified below.
- the ester is hydrolysized by standard saponification methods.
- the acid is then converted to the desired hydroxamate in step 11 by standard coupling procedures including but not limited to EDCI, HOBt or PyBOP and the appropriate hydroxylamine in suitable organic solvents like DMF, THF or methylene chloride.
- Scheme 2 illustrates an example in which the R 8 substituent is on the aniline prior to the coupling procedure with the nitro ester.
- the reaction description is exactly like that for Scheme 1 except that there is no need to incorporated R 8 as it is present in the aniline from the beginning.
- step 3 the preparation of N3 alkyl amino benzimidazole derivatives is illustrated.
- step 1 the terminal alkene of the N3 alkylated benzimidazole hydroxamate is dihydroxylated using a suitable oxidant like OsO 4 in suitable solvent or KMnO 4 or I 2 , AgOAc, AcOH, water.
- the diol is then further oxidized in step 2 by NaIO 4 or Pb(OAc) 4 in suitable biphasic mixture to give the aldehyde.
- step 3 the alkene can be directly converted to the aldehyde by standard methods including but not limited to ozone/Me 2 S, NaIO 4 /OsO 4 or KMnO 4 .
- the amine is prepared by reductive amination using standard methods such as Na(CN)BH 3 , Na(OAc) 3 BH, NMe 4 BH(OAc) 3 with or without AcOH in a suitable solvent such as methylene chloride, acetonitrile or THF.
- a suitable solvent such as methylene chloride, acetonitrile or THF.
- the preferable reduction amination is to treat the aldehyde with amine, Me 4 NBH(OAc) 3 and acetic acid in MeCN at room temperature.
- Scheme 4 illustrates the preparation of compounds of the present invention where W is heterocyclic.
- the methyl ester is converted to the hydrazide by stirring with hydrazine in a suitable solvent like EtOH at temperatures from 50 to 100° C.
- the desired heterocyclic derivative is then prepared by cyclization with the appropriate reagent.
- the hydrazide is treated with an orthoformate like triethyl orthoformate, and an acid catalyst like pTsOH in a suitable organic solvent like EtOH at elevated temperatures (50-100° C.).
- the hydrazide can be cyclized with phosgene or a phosgene equivalent like triphosgene or carbonyl diimidazole in a suitable organic solvent like toluene at temperatures ranging from 50 to 120° C.
- the mercapto oxadizaole 23 can be prepared by reaction with carbon disulfide, and base like KOH in suitable organic solvent like EtOH at elevated temperatures (50-100° C.).
- the amino oxadiazole 24 can be made by reaction with BrCN and base like NaHCO 3 , in a suitable biphasic solvent system like dioxane and water at room temperature.
- the substituted amino oxadiazole 25 can be prepared by first reacting the hydrazide with an appropriate isothiocyanate in a suitable organic solvent like DMF or THF at temperatures ranging from 25 to 100° C.
- the intermediate can be isolated or can be cyclized directly with the treatment of EDCI or other carbodiimide in suitable organic solvent like THF or DMF at temperatures ranging from room temperature to 80° C.
- step 1 the methyl ester is converted to the benzyl alcohol by standard reductive methods, preferably LAH in THF at 0° C. or NaBH 4 in EtOH:THF at room temperature. Oxidation to the aldehyde can be accomplished in step 2 using MnO 2 in acetone:THF at 50° C.
- step 3 organometallic reageants, such as organolithium reagents and Grignard reagents, can be added to the aldehyde in THF at low temperature (e.g., ⁇ 78° C.) to give the substituted benzyl alcohol.
- the keto derivatives can be prepared in step 4 by oxidation of the benyzl alcohol under standard conditions such as Swem or Dess-Martin oxidation.
- the compounds of the present invention may have asymmetric carbon atoms.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
- Enantiomers can be separated by converting the enantiomer mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention.
- the activity of the compounds of the present invention may be determined by the following procedure. N-terminal 6 His-tagged, constitutively active MEK1 (2-393) is expressed in E. coli and protein is purified by conventional methods (Ahn et al., Science 1994, 265, 966-970). The activity of MEK1 is assessed by measuring the incorporation of ⁇ - 33 P-phosphate from ⁇ - 33 P-ATP onto N-terminal His tagged ERK2, which is expressed in E. coli and is purified by conventional methods, in the presence of MEK1. The assay is carried out in 96-well polypropylene plate.
- the incubation mixture (100 ⁇ L) comprises of 25 mM Hepes, pH 7.4, 10 mM MgCl 2 , 5 mM ⁇ -glycerolphosphate, 100 ⁇ M Na-orthovanadate, 5 mM DTT, 5 nM MEK1, and 1 ⁇ M ERK2.
- Inhibitors are suspended in DMSO, and all reactions, including controls are performed at a final concentration of 1% DMSO. Reactions are initiated by the addition of 10 ⁇ M ATP (with 0.5 gCi ⁇ - 33 P-ATP/well) and incubated at ambient temperature for 45 minutes. Equal volume of 25% TCA is added to stop the reaction and precipitate the proteins.
- Precipitated proteins are trapped onto glass fiber B filterplates, and excess labeled ATP washed off using a Tomtec MACH III harvester. Plates are allowed to air-dry prior to adding 30 ⁇ L/well of Packard Microscint 20, and plates are counted using a Packard TopCount. In this assay, compounds of the invention exhibited an IC 50 of less than 50 micromolar.
- Administration of the compounds of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.
- an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
- the active compound may be applied as a sole therapy or may involve one or more other anti-tumor substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; anti-metabolites, for example 5-fluorouracil, cytosine arabinside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No.
- mitotic inhibitors for example vinblastine
- alkylating agents for example cis-platin, carboplatin and cyclophosphamide
- anti-metabolites for example 5-fluorouracil, cytosine arabinside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No.
- the pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
- the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
- the pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
- Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
- Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents.
- the pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
- excipients such as citric acid
- disintegrants such as starch, alginic acid and certain complex silicates
- binding agents such as sucrose, gelatin and acacia.
- lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes.
- Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules.
- Preferred materials include lactose or milk sugar and high molecular weight polyethylene glycols.
- active compound may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
- the starting materials and various intermediates may be obtained from commercial sources, prepared from commercially available organic compounds, or prepared using well known synthetic methods.
- Step B 4-Amino-2,3-difluoro-5-nitro-benzoic acid 3
- Step C 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 4
- Step D 4-Amino-3-fluoro-5-nitro-2-o-tolylamino-benzoic acid methyl ester 5a
- Step E 7-Fluoro-6-o-tolylamino-1H-benzoimidazole-5-carboxylic acid methyl ester 7a
- Step F 7-Fluoro-6-(4-bromo-2-methyl-phenylamino)-1H-benzoimidazole-5-carboxylic acid methyl ester 8a
- Step G 7-Fluoro-6-(4-bromo-2-methyl-phenylamino)-1H-benzoimidazole-5-carboxylic acid 10a
- Step H 7-Fluoro-6-(4-bromo-2-methyl-phenylamino)-1H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 11a
- Step A 4-Amino-3-fluoro-5-nitro-2-phenylamino-benzoic acid methyl ester 26a
- Step B 7-Fluoro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 27a
- Step A 6-(4-Bromo-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 28a
- Step B 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8b
- reaction mixture is quenched by the addition of aqueous saturated sodium bisulfite solution and diluted with ethyl acetate and water and the layers separated.
- the aqueous layer is extracted with ethyl acetate.
- the combined organic extracts are washed with brine, dried (Na 2 SO 4 ) and concentrated under reduced pressure.
- the resulting solid residue is triturated with methylene chloride to yield a white solid which is collected by filtration to yield 1.05 g (85%) of the pure desired product.
- Step A 4-Amino-3-fluoro-2-(2-fluoro-phenylamino)-5-nitro-benzoic acid methyl ester 5b
- Step B 6-(4-Bromo-2-fluoro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8d
- Step A 4-Amino-3-fluoro-2-(2-methyl-4-trifluoromethoxy-phenylamino)-5-nitro-benzoic acid methyl ester 12a
- Step B 7-Fluoro-6-(2-methyl-4-trifluoromethoxy-phenylamino)-3H-benzoimidazole-5-carboxylic acid methyl ester 8f
- Hydroxylamines useful for synthesizing compounds of the present invention may be prepared as follows
- Step A 2-(2-Methoxy-ethoxy)-isoindole-1,3-dione
- Step B O-(2-Methoxy-ethyl)-hydroxylamine
- O-(2-Piperidin-1-yl-ethyl)-hydroxylamine is purified by Kugelrohr distillation (chamber temperature 140° C., 1 torr).
- O-(2-Methylsulfanyl-ethyl)-hydroxylamine is purified by vacuum distillation (76-78° C., 20 torr).
- O-(2-Phenylsulfanyl-ethyl)-hydroxylamine is used directly without purification.
- O-(2-Benzenesulfonyl-ethyl)-hydroxylamine is purified by flash chromatography (1% MeOH in CH 2 Cl 2 ).
- O-(3-Phenylsulfanyl-propyl)-hydroxylamine is prepared from PhSCH 2 CH 2 CH 2 Br and N-hydroxyphthalimide by the patent procedure WO 0018790 and then is deprotected by the procedure described above and used directly without purification.
- O-(3-Benzenesulfonyl-propyl)-hydroxylamine is prepared from the above isoindole-1,3-dione through its oxidation with oxone followed by deprotection as described above and is purified by flash chromatography (100% CH 2 Cl 2 to 2% MeOH in CH 2 Cl 2 ).
- Step A O-(2-Bromo-ethyl)-hydroxylamine hydrobromide
- 2-(2-Bromo-ethoxy)-isoindole-1,3-dione is prepared from 1,2-dibromoethane and N-hydroxyphthalimide as described in WO 0018790, and is then subjected to the procedure in J. Org. Chem. 1963, 28, 1604 to yield the desired product.
- Step B (2-Bromo-ethoxy)-carbamic acid tert-butyl ester
- Step C (2-Morpholin-4-yl-ethoxy)-carbamic acid tert-butyl ester
- Step D O-(2-Morpholin-4-yl-ethyl)-hydroxylamine dihydrochloride
- the isoindole-1,3-dione intermediates of the following hydroxylamines are prepared from the appropriate alkyl halide and N-hydroxyphthalimide by the procedure described within J. Heterocyclic Chem. 2000, 37, 827-830.
- the isoindole-1,3-diones are deprotected by the procedure described above: O-but-3-enyl-hydroxylamine; O-(tetrahydro-furan-2-ylmethyl)-hydroxylamine; O-(3-methoxy-propyl)-hydroxylamine; and O-(3-benzyloxy-propyl)-hydroxylamine.
- Step A 4-Amino-2-(2-chloro-phenylamino)-3-fluoro-5-nitro-benzoic acid methyl ester 5b
- Step B 4,5-Diamino-2-(2-chloro-phenylamino)-3-fluoro-benzoic acid methyl ester 6a
- Step C 6-(2-Chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 7b
- Step D 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8b
- Step E 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid 10b
- Step F 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide (11b)
- Step A 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester 9a and 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-1-methyl-1H-benzoimidazole-5-carboxylic acid methyl ester
- Step B 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid 10c
- aqueous solution is acidified to pH 2 by the addition of 1.0 M aqueous HCl and extracted with 1:1 tetrahydrofuran/ethyl acetate (3 ⁇ ), dried (Na 2 SO 4 ) and concentrated under reduced pressure to provide 43 mg (79%) pure carboxylic acid as an off white solid.
- Step C 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-vinyloxy-ethoxy)-amide 29a
- reaction mixture is diluted with ethyl acetate, washed with water (3 ⁇ ), saturated potassium carbonate (2 ⁇ ), saturated ammonium chloride (2 ⁇ ), brine, dried (Na 2 SO 4 ) and concentrated under reduced pressure to an off-white solid. Trituration of the solid with diethyl ether provides 2.18 g (90%) desired product as an off-white solid. MS ESI (+) m/z 483, 485 (M+ Br pattern) detected.
- Step D 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide 29c
- Step A 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-pent-4-enyl-3H-benzoimidazole-5-carboxylic acid methyl ester 9b
- the organic layer is washed with water and brine, dried (Na 2 SO 4 ) and concentrated under reduced pressure.
- the N3 and N1 alkylated products are separated by flash column chromatography, eluted with 20:1 methylene chloride:ethyl acetate. Complete separation of the isomers is obtained by performing two chromatographic separations.
- the higher R f product is the N3 product 9b, while the lower R f product is the N1 product.
- the recovery of the N3 product 9b is 0.415 g (38%): LC/MS ESI (+) m/z 448, 446 (M+1 Br pattern) detected.
- the recovery of the N1 product was 0.486 g (45%): LC/MS ESI (+) m/z 448, 446 (M+1 Br pattern) detected.
- Step B 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-pent-4-enyl-3H-benzoimidazole-5-carboxylic acid 10d
- Step C 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-pent-4-enyl-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 11f
- Step D 6-(4-Bromo-2-methyl-phenylamino)-3-(4,5-dihydroxy-pentyl)-7-fluoro-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 11m
- reaction mixture is filtered through Celite rinsing with ethyl acetate and methylene chloride.
- the filtrate is diluted with ethyl acetate and washed with 0.01 N HCl, and brine.
- the organic layer is dried (Na 2 SO 4 ) and concentrated under reduced pressure.
- the crude product is purified by FCC eluted with 9:1 ethyl acetate:MeOH to give 0.244 g (74%) pure desired product.
- Step E 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-(4-oxo-butyl)-3H benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 11n
- Step F 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3-[4-(4-methyl-piperazin-1-yl)-butyl]-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 11o
- step F The following compounds are prepared by methods similar to those described in Example 19 by using the appropriate alkenyl substituted benzimidazole and the appropriate amine in the reductive amination (step F): 18a 18b 18c 18d 18e 18f 18g 18h 18i 18j 18k 18l 18m 18n 18o 18p 18q 18r 18s 18t 18u 18v 18w 18x 18y 18z 18aa 18bb
- Step A 6-(4-Bromo-2-chloro-phenylamino)-3-(2-tert-butoxycarbonyl-ethyl)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester
- Step B 6-(4-Bromo-2-chloro-phenylamino)-3-(2-carboxy-ethyl)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester TFA salt
- Step C 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-1-yl-propyl)-3H-benzoimidazole-5-carboxylic acid methyl ester
- Step D 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-1-yl-propyl)-3H-benzoimidazole-5-carboxylic acid
- Step E 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(3-oxo-3-pyrrolidin-1-yl-propyl)-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 18hhh
- Step A 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid methyl ester 11q
- Step B 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid 11r
- reaction mixture is poured into a separatory funnel and diluted with ethyl acetate/tetrahydrofuran and water and the layers separated.
- the aqueous layer is extracted with ethyl acetate.
- the combined organic layers are washed with brine, dried (Na 2 SO 4 ) and concentrated under reduced pressure to yield 0.11 g (100%) of the pure desired product as a white solid.
- Step C 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid (2-vinyloxy-ethoxy)-amide 11s
- O-(2-vinyloxy-ethyl)-hydroxylamine (0.028 g, 0.27 mmol) and EDCI (0.056 g, 0.29 mmol) are added and the reaction mixture is stirred at room temperature under N 2 until HPLC shows the reaction is complete (2-3 days).
- the reaction mixture is poured into a separatory funnel, diluted with ethyl acetate and water and the layers separated. The ethyl acetate layer is washed successively with aqueous saturated NH 4 Cl (2 ⁇ ), brine (1 ⁇ ), aqueous saturated sodium bicarbonate (2 ⁇ ), water (1 ⁇ ), and brine (1 ⁇ ), dried (Na 2 SO 4 ) and concentrated under reduced pressure.
- Step D 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(tetrahydro-pyran-2-ylmethyl)-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide 11p
- Step A 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carboxylic acid methyl ester 11cc
- Step B 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 11bb
- 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carboxylic acid methyl ester 11cc is subjected to methods previously described to give 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide: MS APCI (+) m/z 561, 559 (M+ Br pattern) and MS APCI ( ⁇ ) m/z 559, 557 (M ⁇ Br pattern) detected; 1 H NMR (400 MHz, DMSO-d 6 ) ⁇ 11.75 (s, 1H), 8.47 (s, 1H), 8.04 (s, 1H), 7.77 (s, 1H), 7.62 (d, 1H),
- Step A 6-(4-Bromo-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid hydrazide 20a
- Step B [6-(5-Amino-[1,3,4]oxadiazol-2-yl)-4-fluoro-1H-benzoimidazol-5-yl]-(4-bromo-2-methyl-phenyl)-amine 24a
- [0312] [6-(5-Amino-[1,3,4]oxadiazol-2-yl)-4-fluoro-1H-benzoimidazol-5-yl]-(4-chloro-2-methyl-phenyl)-amine 24b is prepared as described in example 31 starting with 6-(4-chloro-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8e.
- [0315] [6-(5-Amino-[1,3,4]oxadiazol-2-yl)-4-fluoro-1H-benzoimidazol-5-yl]-(4-bromo-2-chloro-phenyl)-amine 24c is prepared as described in example 31 starting with 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8b.
- 6-(4-Chloro-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid hydrazide 20b is prepared as described in example 31, step A from 6-(4-chloro-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid methyl ester 8e.
- the reaction mixture is poured into a separatory funnel and diluted with ethyl acetate and water and the layers separated.
- the ethyl acetate layer is washed successively with aqueous saturated NH 4 Cl (2 ⁇ ), brine (1 ⁇ ), aqueous saturated sodium bicarbonate (2 ⁇ ), water (1 ⁇ ), and brine (1 ⁇ ), dried (MgSO 4 ) and concentrated under reduced pressure.
- the resulting solid is purified by FCC (cluting with 19:1 methylene chloride:methanol) to yield 0.013 g (42%) of the pure desired product.
- the filtrate is concentrated under reduced pressure to a small volume and then filtered through an Acrodisc syringe filter to remove small amounts of MnO 2 that passed through the silica gel.
- the filtrate is concentrated under reduced pressure and the residue is purified by flash column chromatography (eluting with 20:1 methylene chloride:methanol) to yield 0.81 g (85%) of the pure desired product as a bright yellow solid.
- Step A 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazol-5-yl]-2-methoxymethoxy-ethanol 10i
- Step B 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazol-5-yl]-2-methoxymethoxy-ethanone 10j
- Step C 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazol-5-yl]-2-hydroxy-ethanone 10g
- Step A 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methoxymethoxy-ethanol 101
- Step B 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methoxymethoxy-ethanone 10m
- reaction mixture is slowly warmed to room temperature, stirred for 5 min at room temperature, and diluted with water and CH 2 Cl 2 .
- the organic layer is separated, dried over MgSO 4 , filtered, and concentrated to give the crude product which is directly used without further purification.
- Step C 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-hydroxy-ethanone 10k
- Step A 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-ethoxy-ethanol 10o
- Step B 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-ethoxy-ethanone 10n
- the title compound is prepared from 1-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-ethoxy-ethanol 10o according to the procedure described in Example 42, Step B except that the reaction mixture is not treated with saturated aqueous NaHCO 3 containing sodium thiosulfate pentahydrate.
- Step A 2-Benzyloxy-1-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-ethanol 10r
- Step B 2-Benzyloxy-1-[6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-ethanone 10q
- Step A 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methanesulfonyl-ethanol 10t
- Step B 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-methanesulfonyl-ethanone 10s
- Step A 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-2-(isopropoxy-dimethyl-silanyl)-ethanol 10v
- Step B 1-[6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3H-benzoimidazol-5-yl]-ethane-1,2-diol 10u
- Step A [6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazol-5-yl]-methanol 10y
- Step B 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-(2-methanesulfonyl-ethyl)-3H-benzoimidazole-5-carbaldehyde 10z
- reaction mixture is concentrated to dryness and the residue dissolved in 10:1 methylene chloride:MeOH.
- the solution is filtered through a silica gel plug eluted with 10:1 methylene chloride:MeOH.
- the resulting filtrate is concentrated under reduced pressure to give 41 mg (82%) desired product as a bright yellow solid.
- Step C (4-Bromo-2-chloro-phenyl)-(4-fluoro-6-oxazol-5-yl-1H-benzoimidazol-5-yl)-amine 10x
- Step A (4-Bromo-2-chloro-phenyl)- ⁇ 4fluoro-1-(2-methanesulfonyl-ethyl)-6-[4-(toluene-4-sulfonyl)-4,5-dihydro-oxazol-5-yl]-1H-benzoimidazol-5-yl ⁇ -amine 10bb
- Step B (4-Bromo-2-chloro-phenyl)-[4-fluoro-6-(3H-imidazol-4-yl)-1H-benzoimidazol-5-yl]-amine 10aa
- Step A 3-Chloro-2,4-difluoro-5-nitro-benzoic acid 2a
- Step B 4-Amino-3-chloro-2-fluoro-5-nitro-benzoic acid 3a
- Step C 4-Amino-3-chloro-2-fluoro-5-nitro-benzoic acid methyl ester 4a
- Step D 4-Amino-3-chloro-5-nitro-2-phenylamino-benzoic acid methyl ester 5c
- Step E 4,5-Diamino-3-chloro-2-phenylamino-benzoic acid methyl ester 6b
- Step F 7-Chloro-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 7c
- Step G 6-(4-Bromo-phenylamino)-7-chloro-3H-benzoimidazole-5-carboxylic acid methyl ester 8g
- Step H 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3H-benzoimidazole-5-carboxylic acid methyl ester 10dd
- Step I 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid methyl ester 10ee
- N3 and N1 alkylated regioisomers are separated by flash chromatography (EtOAc).
- EtOAc flash chromatography
- Step J 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid 10ff
- Step K 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-vinyloxy-ethoxy)-amide 10gg
- Step L 6-(4-Bromo-2-chloro-phenylamino)-7-chloro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide 10cc
- Step A 4,5-Diamino-3-fluoro-2-phenylamino-benzoic acid methyl ester 6c
- Step B 7-Fluoro-2-methyl-6-phenylamino-3H-benzoimidazole-5-carboxylic acid methyl ester 31a
- Step C 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-2-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide 10ii
- Step A 7-Fluoro-6-(4-iodo-2-methyl-phenylamino)-1H-benzoimidazole-5-carboxylic acid methyl ester 10jj
- reaction mixture is quenched by the addition of 10% Na 2 S 2 O 4 solution.
- the reaction mixture is then diluted with water and ethyl acetate and the layers separated.
- the aqueous layer is extracted with ethyl acetate.
- the combined organic extracts are dried (Na 2 SO 4 ) and concentrated under reduced pressure.
- the recovered solid is triturated with MeOH to give 1.45 g (69%) pure desired product: MS ESI (+) m/z 426 (M+1) detected; MS ESI ( ⁇ ) m/z 424 (M ⁇ 1) detected.
- Step B 7-Fluoro-6-(4-iodo-2-methyl-phenylamino)-(2-trimethylsilanyl-ethoxymethyl)-benzoimidazole-5-carboxylic acid methyl ester 10kk
- reaction mixture is quenched by the addition of water and brine.
- the reaction mixture is extracted with ethyl acetate.
- the combined organic extracts are washed with water and brine, and dried (MgSO 4 ) and concentrated under reduced pressure. Purification by flash column chromatography eluted with 1:1 hexanes:ethyl acetate gives 0.182 g (70%) of desired product as a 1:1 mixture of N1 and N3 isomers as a white foam.
- Step C 6-(4-Cyano-2-methyl-phenylamino)-7-fluoro-(2-trimethylsilanyl-ethoxymethyl)-benzoimidazole-5-carboxylic acid methyl ester 10ll
- Step D 6-(4-Cyano-2-methyl-phenylamino)-7-fluoro-(2-trimethylsilanyl-ethoxymethyl)-benzoimidazole-5-carboxylic acid 10mm
- Step E 6-(4-Cyano-2-methyl-phenylamino)-7-fluoro-(2-trimethylsilanyl-ethoxymethyl)-benzoimidazole-5-carboxylic acid cyclopropylmethyoxy-amide 11zz
- Step F 6-(4-Cyano-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid cyclopropylmethyoxy-amide 11yy
- Step A 7-Fluoro-6-(2-methyl-4-trimethylsilanylethynyl-phenylamino)-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 11bbb
- Step B 6-(4-Ethynyl-2-methyl-phenylamino)-7-fluoro-3H-benzoimidazole-5-carboxylic acid cyclopropylmethoxy-amide 11aaa
- reaction mixture is stirred at 50° C. for 2 hours under N 2 .
- the reaction mixture is cooled to room temperature, a few drops of H 2 O are added and then it is concentrated under reduced pressure.
- the residue is purified by FCC (eluting with 20:1 methylene chloride:methanol) to yield 0.011 g (65%) of the pure desired product.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/387,879 US20030232869A1 (en) | 2002-03-13 | 2003-03-13 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US10/652,733 US7235537B2 (en) | 2002-03-13 | 2003-08-29 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
BRPI0306026A BRPI0306026B8 (pt) | 2003-03-13 | 2003-12-12 | composto, composição farmaceutica e uso de um composto |
BR122018007328A BR122018007328B8 (pt) | 2002-03-13 | 2003-12-12 | composto, composição farmaceutica e uso do dito composto |
US11/061,336 US7425637B2 (en) | 2002-03-13 | 2005-02-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US11/762,897 US7842816B2 (en) | 2002-03-13 | 2007-06-14 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/050,827 US7777050B2 (en) | 2002-03-13 | 2008-03-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/050,847 US7576114B2 (en) | 2002-03-13 | 2008-03-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,559 US8178693B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,497 US7973170B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,477 US8003805B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,521 US8193229B2 (en) | 2002-03-13 | 2010-06-28 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,547 US8193230B2 (en) | 2002-03-13 | 2010-06-28 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof |
US12/826,158 US8193231B2 (en) | 2002-03-13 | 2010-06-29 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof |
US13/463,487 US8513293B2 (en) | 2002-03-13 | 2012-05-03 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36400702P | 2002-03-13 | 2002-03-13 | |
US10/387,879 US20030232869A1 (en) | 2002-03-13 | 2003-03-13 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/652,733 Continuation-In-Part US7235537B2 (en) | 2002-03-13 | 2003-08-29 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US11/061,336 Continuation US7425637B2 (en) | 2002-03-13 | 2005-02-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030232869A1 true US20030232869A1 (en) | 2003-12-18 |
Family
ID=28041856
Family Applications (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/387,879 Abandoned US20030232869A1 (en) | 2002-03-13 | 2003-03-13 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US11/061,336 Expired - Lifetime US7425637B2 (en) | 2002-03-13 | 2005-02-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/050,847 Expired - Lifetime US7576114B2 (en) | 2002-03-13 | 2008-03-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/050,827 Expired - Lifetime US7777050B2 (en) | 2002-03-13 | 2008-03-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,521 Expired - Fee Related US8193229B2 (en) | 2002-03-13 | 2010-06-28 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,547 Expired - Fee Related US8193230B2 (en) | 2002-03-13 | 2010-06-28 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof |
US12/824,477 Expired - Lifetime US8003805B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,497 Expired - Lifetime US7973170B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,559 Expired - Fee Related US8178693B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/826,158 Expired - Fee Related US8193231B2 (en) | 2002-03-13 | 2010-06-29 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof |
US13/463,487 Expired - Lifetime US8513293B2 (en) | 2002-03-13 | 2012-05-03 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Family Applications After (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/061,336 Expired - Lifetime US7425637B2 (en) | 2002-03-13 | 2005-02-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/050,847 Expired - Lifetime US7576114B2 (en) | 2002-03-13 | 2008-03-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/050,827 Expired - Lifetime US7777050B2 (en) | 2002-03-13 | 2008-03-18 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,521 Expired - Fee Related US8193229B2 (en) | 2002-03-13 | 2010-06-28 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,547 Expired - Fee Related US8193230B2 (en) | 2002-03-13 | 2010-06-28 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof |
US12/824,477 Expired - Lifetime US8003805B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,497 Expired - Lifetime US7973170B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/824,559 Expired - Fee Related US8178693B2 (en) | 2002-03-13 | 2010-06-28 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US12/826,158 Expired - Fee Related US8193231B2 (en) | 2002-03-13 | 2010-06-29 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof |
US13/463,487 Expired - Lifetime US8513293B2 (en) | 2002-03-13 | 2012-05-03 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Country Status (35)
Country | Link |
---|---|
US (11) | US20030232869A1 (sr) |
EP (5) | EP2130536B1 (sr) |
JP (4) | JP4093966B2 (sr) |
KR (3) | KR100984595B1 (sr) |
CN (4) | CN100519539C (sr) |
AR (3) | AR038971A1 (sr) |
AT (1) | ATE449605T1 (sr) |
AU (2) | AU2003218157C1 (sr) |
BE (1) | BE2019C510I2 (sr) |
BR (1) | BR122018007328B8 (sr) |
CA (1) | CA2478374C (sr) |
CL (2) | CL2012002380A1 (sr) |
CY (3) | CY1109727T1 (sr) |
DE (1) | DE60330227D1 (sr) |
DK (4) | DK1482932T3 (sr) |
DO (4) | DOP2003000613A (sr) |
ES (5) | ES2635666T3 (sr) |
HK (3) | HK1070823A1 (sr) |
HU (2) | HUE025767T2 (sr) |
IL (4) | IL163995A0 (sr) |
IS (4) | IS2748B (sr) |
LT (1) | LTC1482932I2 (sr) |
LU (1) | LUC00100I2 (sr) |
MX (1) | MXPA04008893A (sr) |
NL (1) | NL300974I2 (sr) |
NZ (1) | NZ535158A (sr) |
PA (1) | PA8569301A1 (sr) |
PL (5) | PL401637A1 (sr) |
PT (4) | PT2130537E (sr) |
SG (3) | SG194238A1 (sr) |
SI (4) | SI2130537T1 (sr) |
TW (3) | TWI350285B (sr) |
UA (1) | UA77765C2 (sr) |
WO (1) | WO2003077914A1 (sr) |
ZA (1) | ZA200407220B (sr) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050054701A1 (en) * | 2003-09-03 | 2005-03-10 | Eli Wallace | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005051300A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
US20050130954A1 (en) * | 2003-11-21 | 2005-06-16 | Mitchell Ian S. | AKT protein kinase inhibitors |
US20050171182A1 (en) * | 2003-12-11 | 2005-08-04 | Roger Briesewitz | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
US20050256123A1 (en) * | 2003-11-19 | 2005-11-17 | Marlow Allison L | Heterocyclic inhibitors of MEK and methods of use thereof |
US20060030610A1 (en) * | 2003-09-03 | 2006-02-09 | Kevin Koch | Method of treating inflammatory diseases |
US20070112038A1 (en) * | 2003-11-19 | 2007-05-17 | Marlow Allison L | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2007002157A3 (en) * | 2005-06-23 | 2007-11-01 | Array Biopharma Inc | Process for preparing benzimidazole compounds |
US20080051399A1 (en) * | 2006-07-06 | 2008-02-28 | Mitchell Ian S | Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US20080058327A1 (en) * | 2006-07-06 | 2008-03-06 | Mitchell Ian S | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US20080280957A1 (en) * | 2005-05-18 | 2008-11-13 | Array Biopharma, Inc. | Heterocyclic Inhibitors of Mek and Methods of Use Thereof |
US20090030058A1 (en) * | 2005-12-21 | 2009-01-29 | Mohammed Pervez | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
US20100016393A1 (en) * | 2005-12-21 | 2010-01-21 | Demattei John | Novel hydrogen sulfate salt |
US20100069381A1 (en) * | 2006-08-03 | 2010-03-18 | Fumio Itoh | Gsk-3betainhibitor |
WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
US20100130748A1 (en) * | 2005-06-23 | 2010-05-27 | Array Biopharma Inc. | Snar process for preparing benzimidazole compounds |
US20100292244A1 (en) * | 2008-01-09 | 2010-11-18 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
US20110065716A1 (en) * | 2008-01-09 | 2011-03-17 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
US20110160221A1 (en) * | 2007-07-05 | 2011-06-30 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
WO2012085244A1 (fr) | 2010-12-23 | 2012-06-28 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
US8513293B2 (en) | 2002-03-13 | 2013-08-20 | Array Biopharma Inc. | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
US8618097B2 (en) | 2007-07-05 | 2013-12-31 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US9150549B2 (en) | 2011-04-01 | 2015-10-06 | Genentech, Inc. | Combinations of AKT inhibitor compounds and erlotinib, and methods of use |
US9303040B2 (en) | 2006-07-06 | 2016-04-05 | Array Biopharma Inc. | Substituted piperazines as AKT inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US9682082B2 (en) | 2011-04-01 | 2017-06-20 | Genentech, Inc. | Combinations of AKT and MEK inhibitor compounds, and methods of use |
Families Citing this family (212)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US20060084682A1 (en) * | 2002-12-13 | 2006-04-20 | Heerding Dirk A | Thrombopoietin mimetics |
DE602004020741D1 (de) * | 2003-02-26 | 2009-06-04 | Kowa Co | Mittel zur behandlung der allergischen kontaktdermatitis |
BRPI0412851A (pt) * | 2003-07-24 | 2006-10-03 | Warner Lambert Co | benzamidazóis de n-metila-substituìdos |
ATE472534T1 (de) | 2003-09-22 | 2010-07-15 | S | Benzimidazolderivate: herstellung und pharmazeutische anwendungen |
JP5214971B2 (ja) | 2004-10-20 | 2013-06-19 | メルク セローノ ソシエテ アノニム | 3−アリルアミノピペリジン誘導体 |
ATE443063T1 (de) * | 2004-12-01 | 2009-10-15 | Merck Serono Sa | Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen |
US7429667B2 (en) * | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
AU2013203939B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
JP5129143B2 (ja) | 2005-10-07 | 2013-01-23 | エグゼリクシス, インコーポレイテッド | Mekインヒビターおよびその使用方法 |
AU2012261703B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7968108B2 (en) * | 2005-10-25 | 2011-06-28 | Metbro Distributing L.P. | Hydrogen cyanamide pesticide formulations |
US7572460B2 (en) * | 2005-10-25 | 2009-08-11 | Rodrigo Rodriguez-Kabana | Hydrogen cyanamide pesticide formulations |
CA2534243A1 (fr) | 2006-01-25 | 2007-07-25 | Hydro Quebec | Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
JP5269762B2 (ja) * | 2006-04-18 | 2013-08-21 | アーディア・バイオサイエンシーズ・インコーポレイテッド | Mek阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド |
ATE531720T1 (de) * | 2006-08-21 | 2011-11-15 | Genentech Inc | Aza-benzofuranylverbindungen und anwendungsverfahren dafür |
CN101583616B (zh) * | 2006-08-21 | 2012-05-30 | 健泰科生物技术公司 | 氮杂苯并噻吩基化合物及使用方法 |
KR101475088B1 (ko) * | 2006-08-21 | 2014-12-23 | 제넨테크, 인크. | 아자-벤조티오페닐 화합물 및 사용 방법 |
CN101605540A (zh) | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
JP2010523634A (ja) * | 2007-04-13 | 2010-07-15 | アストラゼネカ アクチボラグ | Azd2171およびazd6244またはmek阻害剤iiを含む併用療法 |
US8509487B2 (en) * | 2007-04-19 | 2013-08-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for optically measuring a parameter of an object |
WO2008157179A2 (en) | 2007-06-12 | 2008-12-24 | Genentech, Inc. | N-substituted azaindoles and methods of use |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
BRPI0818426A2 (pt) * | 2007-10-15 | 2017-06-13 | Astrazeneca Ab | produto de combinação, uso de um produto de combinação, e, método para tratar câncer |
EP2227469B9 (en) | 2007-11-12 | 2014-09-10 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
JP5421925B2 (ja) | 2007-12-19 | 2014-02-19 | ジェネンテック, インコーポレイテッド | 5−アニリノイミダゾピリジン及び使用の方法 |
PT2231662E (pt) | 2007-12-19 | 2011-09-12 | Genentech Inc | 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios |
BRPI0820696A2 (pt) | 2007-12-20 | 2019-09-24 | Hoffmann La Roche | hidantoínas substituídas como inibidores de cinase de mek |
EP2220092B1 (en) | 2007-12-21 | 2012-06-06 | Genentech, Inc. | Azaindolizines and methods of use |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
EP2293472A1 (en) | 2008-06-23 | 2011-03-09 | Panasonic Corporation | Wireless communication base station apparatus and reference signal allocation method |
CN102137847B (zh) | 2008-07-01 | 2015-06-10 | 健泰科生物技术公司 | 作为mek激酶抑制剂的二环杂环 |
CN102137843A (zh) | 2008-07-01 | 2011-07-27 | 健泰科生物技术公司 | 作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法 |
HUE027223T2 (en) | 2008-08-04 | 2016-08-29 | Merck Patent Gmbh | New Phenylamino Isonicotinamide Compounds |
CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资(香港)有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
EP2358202B1 (en) * | 2008-11-03 | 2016-06-15 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
JP2013529619A (ja) | 2010-06-25 | 2013-07-22 | ノバルティス アーゲー | タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物 |
CN103221043B (zh) | 2010-08-05 | 2016-04-06 | 卡斯西部储备大学 | 用于治疗神经元连接发育障碍的erk抑制剂 |
US20130196990A1 (en) | 2010-10-06 | 2013-08-01 | Junya Qu | Benzimidazole Derivatives As PI3 Kinase Inhibitors |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
CN103380212B (zh) | 2010-12-22 | 2017-04-05 | 菲特治疗公司 | 用于单细胞分选与增强ipsc重新编程的细胞培养平台 |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
WO2012162293A1 (en) * | 2011-05-23 | 2012-11-29 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
WO2012160130A1 (en) | 2011-05-25 | 2012-11-29 | Universite Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
AU2012333092B2 (en) * | 2011-08-31 | 2016-04-21 | Novartis Ag | Synergistic combinations of PI3K- and MEK-inhibitors |
CA2845571A1 (en) * | 2011-09-01 | 2013-03-07 | Novartis Ag | Use of organic compound for the treatment of noonan syndrome |
EP2570127A1 (en) | 2011-09-16 | 2013-03-20 | Sanofi | Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors |
JP2014530243A (ja) | 2011-10-14 | 2014-11-17 | アレイ バイオファーマ、インコーポレイテッド | Arry−380の多形体、選択的herb2阻害剤、およびそれらを含有する薬学的組成物 |
US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法 |
EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
BR112014012539B1 (pt) | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
JP6158833B2 (ja) | 2012-01-09 | 2017-07-05 | アローヘッド ファーマシューティカルズ インコーポレイテッド | ベータ−カテニン関連疾患を処置するための有機組成物 |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
AU2013235596B9 (en) | 2012-03-20 | 2017-12-14 | Amgen Inc. | Combination therapy of a MEK inhibitor and IGF1R inhibitor |
EP2836873B1 (en) | 2012-04-09 | 2020-03-11 | Switch Materials, Inc. | Switching materials, and compositions and methods for making same |
US9588358B2 (en) | 2012-05-29 | 2017-03-07 | Switch Materials, Inc. | Optical filter comprising a variable transmittance layer |
KR20150013332A (ko) | 2012-05-31 | 2015-02-04 | 바이엘 파마 악티엔게젤샤프트 | 간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커 |
AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
CA2879252C (en) | 2012-08-17 | 2017-10-10 | F. Hoffmann-La Roche Ag | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
NZ706635A (en) | 2012-10-02 | 2018-08-31 | Gilead Sciences Inc | Inhibitors of histone demethylases |
SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | A novel process for the manufacture of compounds for use in the treatment of cancer |
DK2909181T3 (da) | 2012-10-16 | 2017-11-20 | Tolero Pharmaceuticals Inc | PKM2-modulatorer og fremgangsmåder til anvendelse deraf |
CA3079071C (en) * | 2012-10-19 | 2022-06-07 | Array Biopharma Inc. | Preparation of crystallized benzimidazole derivative as mek inhibitor and formulation comprising same |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
WO2014085381A1 (en) | 2012-11-29 | 2014-06-05 | Novartis Ag | Pharmaceutical combinations |
US9867825B2 (en) | 2012-12-20 | 2018-01-16 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
AU2014218807A1 (en) | 2013-02-22 | 2015-09-03 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
ES2703208T3 (es) | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
SG11201506717UA (en) | 2013-02-27 | 2015-09-29 | Epitherapeutics Aps | Inhibitors of histone demethylases |
KR102334260B1 (ko) | 2013-03-14 | 2021-12-02 | 스미토모 다이니폰 파마 온콜로지, 인크. | Jak2 및 alk2 억제제 및 이들의 사용 방법 |
MX2015013466A (es) * | 2013-03-21 | 2016-06-21 | Novartis Ag | Terapia de combinacion que comprende un inhibidor deb-raf y un segundo inhibidor. |
AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US9624206B2 (en) | 2013-12-19 | 2017-04-18 | Actelion Pharmaceuticals Ltd | Antibacterial 1H-indazole and 1H-indole derivatives |
CA2935804A1 (en) | 2014-01-14 | 2015-07-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
CN104788365B (zh) * | 2014-01-16 | 2018-08-10 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
KR102460549B1 (ko) | 2014-03-04 | 2022-10-28 | 페이트 세러퓨틱스, 인코포레이티드 | 개선된 재프로그래밍 방법 및 세포 배양 플랫폼 |
US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
EP3126345A1 (en) | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
US20170107486A1 (en) | 2014-04-21 | 2017-04-20 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
JP2017515906A (ja) | 2014-05-16 | 2017-06-15 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 抗菌性キナゾロン−4(3h)−オン誘導体 |
US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
AR101210A1 (es) | 2014-07-15 | 2016-11-30 | Genentech Inc | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek |
WO2016033169A1 (en) | 2014-08-27 | 2016-03-03 | Epitherapeutics Aps | Compounds and methods for inhibiting histone demethylases |
WO2016040882A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of egfr inhibitors |
EP3200775B1 (en) | 2014-10-03 | 2019-11-20 | Novartis AG | Combination therapies |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
BR112017007379A2 (pt) | 2014-10-14 | 2017-12-19 | Dana Farber Cancer Inst Inc | moléculas de anticorpo para pd-l1 e usos das mesmas |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
ES2722048T3 (es) | 2014-12-23 | 2019-08-07 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
CN107429230B (zh) | 2015-01-26 | 2021-11-12 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
JP2016155776A (ja) * | 2015-02-24 | 2016-09-01 | 学校法人兵庫医科大学 | 抗腫瘍効果増強剤および抗腫瘍剤 |
WO2016145102A1 (en) | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
AU2016238436A1 (en) | 2015-03-25 | 2017-08-17 | Novartis Ag | Formylated N-heterocyclic derivatives as FGFR4 inhibitors |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
PL3317301T3 (pl) | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
AR105646A1 (es) | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
RU2020142739A (ru) | 2015-08-28 | 2021-01-15 | Новартис Аг | Ингибиторы mdm2 и их комбинации |
AR105889A1 (es) | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos |
SG11201802957PA (en) | 2015-10-16 | 2018-05-30 | Fate Therapeutics Inc | Platform for the induction & maintenance of ground state pluripotency |
KR20180069070A (ko) | 2015-11-03 | 2018-06-22 | 얀센 바이오테크 인코포레이티드 | Tim-3과 특이적으로 결합하는 항체 및 그의 용도 |
CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CN115806940A (zh) | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
US11413309B2 (en) | 2016-01-20 | 2022-08-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
CN108473959B (zh) | 2016-01-20 | 2023-04-21 | 菲特治疗公司 | 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法 |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
US11975002B2 (en) | 2016-03-04 | 2024-05-07 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
SG11201810793XA (en) | 2016-06-03 | 2018-12-28 | Giordano Caponigro | Pharmaceutical combinations |
US10676479B2 (en) | 2016-06-20 | 2020-06-09 | Novartis Ag | Imidazolepyridine compounds and uses thereof |
ES2798424T3 (es) | 2016-06-20 | 2020-12-11 | Novartis Ag | Compuestos de triazolopiridina y usos de estos |
US11091489B2 (en) | 2016-06-20 | 2021-08-17 | Novartis Ag | Crystalline forms of a triazolopyrimidine compound |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
WO2018065924A1 (en) * | 2016-10-04 | 2018-04-12 | Sun Pharmaceutical Industries Limited | Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation |
WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
CN108084078B (zh) * | 2016-11-24 | 2021-07-30 | 中山大学 | 一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法 |
JP7098615B2 (ja) | 2016-12-05 | 2022-07-11 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
EP3372624A1 (en) | 2017-03-06 | 2018-09-12 | Henkel AG & Co. KGaA | One component composition based on compounds with at least two exo-vinylene cyclic carbonate units |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
EP3712133A4 (en) * | 2017-11-14 | 2021-05-12 | Shenzhen TargetRx, Inc. | SUBSTITUTED BENZIMIDAZOLE COMPOUND AND COMPOSITION WITH IT |
WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
EP3769765B1 (en) | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
SG11202011633SA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Psma binding agents and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020021322A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) Srl | Stable, concentrated radionuclide complex solutions |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
EP3826684A4 (en) | 2018-07-26 | 2022-04-06 | Sumitomo Dainippon Pharma Oncology, Inc. | METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE THEREOF |
MX2021001804A (es) | 2018-08-17 | 2021-04-19 | Novartis Ag | Compuestos de urea y composiciones como inhibidores de atpasa de smarca2/brm. |
CN117122707A (zh) | 2018-09-25 | 2023-11-28 | 意大利国际先进加速器应用有限公司 | 联合疗法 |
AU2019383311A1 (en) | 2018-11-20 | 2021-06-10 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
CA3127502A1 (en) | 2019-02-12 | 2020-08-20 | Sumitomo Dainippon Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US11712433B2 (en) | 2019-03-22 | 2023-08-01 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
WO2020212832A1 (en) * | 2019-04-16 | 2020-10-22 | Alembic Pharmaceuticals Limited | Process of preparation of benzimidazole compounds |
CN113747944A (zh) | 2019-04-19 | 2021-12-03 | 詹森生物科技公司 | 用抗psma/cd3抗体治疗前列腺癌的方法 |
TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療braf相關的疾病和失調症之化合物 |
EP3994132A1 (en) | 2019-07-03 | 2022-05-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
WO2021057853A1 (en) | 2019-09-26 | 2021-04-01 | Novartis Ag | Aza-quinoline compounds and uses thereof |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021116901A1 (en) * | 2019-12-09 | 2021-06-17 | Biocon Limited | Forms of binimetinib and process for preparation thereof |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN115380026B (zh) * | 2020-03-17 | 2023-11-07 | 南京明德新药研发有限公司 | 蛋白降解调节剂与其使用方法 |
US20230165862A1 (en) | 2020-04-10 | 2023-06-01 | Taiho Pharmaceutical Co., Ltd. | Cancer therapy using 3,5-disubstituted benzene alkynyl compound and mek inhibitor |
PE20231651A1 (es) | 2020-06-09 | 2023-10-17 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf |
CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
MX2023003867A (es) | 2020-10-05 | 2023-04-18 | Pf Medicament | Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii. |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
CN112759552A (zh) * | 2020-12-31 | 2021-05-07 | 武汉九州钰民医药科技有限公司 | 司美替尼的合成方法 |
CN112679438A (zh) * | 2020-12-31 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | 制备司美替尼的方法 |
CA3205523A1 (en) * | 2021-01-21 | 2022-07-28 | Michael Houghton | Processes for preparing pyrrolopyridine-aniline compounds |
KR20230137393A (ko) | 2021-01-28 | 2023-10-04 | 얀센 바이오테크 인코포레이티드 | Psma 결합 단백질 및 이의 용도 |
IL304891A (en) | 2021-02-02 | 2023-10-01 | Servier Lab | Selective Protech BCL-XL compounds and methods of use |
CN117321418A (zh) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | 癌症生物标志物及其使用方法 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
EP4322953A1 (en) * | 2021-04-15 | 2024-02-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a pkc inhibitor and a mek inhibitor |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
IL307964A (en) | 2021-06-09 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | Combined treatment for cancer |
WO2022262699A1 (zh) * | 2021-06-17 | 2022-12-22 | 深圳市塔吉瑞生物医药有限公司 | 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途 |
WO2023283425A1 (en) | 2021-07-09 | 2023-01-12 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
CN118201615A (zh) | 2021-11-04 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 喹唑啉酮化合物用于治疗癌症的新用途 |
WO2023084489A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
TW202404645A (zh) | 2022-05-20 | 2024-02-01 | 瑞士商諾華公司 | Met bcl-xl抑制劑抗體-藥物結合物及其使用方法 |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023238000A1 (en) * | 2022-06-06 | 2023-12-14 | Glenmark Life Sciences Limited | Process for preparation of selumetinib and salts thereof |
WO2024105144A1 (en) | 2022-11-18 | 2024-05-23 | F. Hoffmann-La Roche Ag | Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
US6469004B1 (en) * | 1999-01-13 | 2002-10-22 | Warner-Lambert Company | Benzoheterocycles and their uses as MEK inhibitors |
US6506798B1 (en) * | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
US20030078428A1 (en) * | 1997-07-01 | 2003-04-24 | Barrett Stephen Douglas | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
US20030092748A1 (en) * | 1999-01-13 | 2003-05-15 | Barrett Stephen Douglas | Benzenesulfonamide derivatives and their use as MEK inhibitors |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55501033A (sr) | 1978-11-20 | 1980-11-27 | ||
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5250554A (en) * | 1989-10-24 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives useful as angiotensin II inhibitors |
IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
US5218356A (en) * | 1991-05-31 | 1993-06-08 | Guenther Knapp | Wireless indoor data relay system |
US5216003A (en) * | 1992-01-02 | 1993-06-01 | G. D. Searle & Co. | Diacid-containing benzimidazole compounds for treatment of neurotoxic injury |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
PE27997A1 (es) | 1994-04-29 | 1997-09-20 | Lilly Co Eli | Antagonistas de receptores de taquicininas |
US5520187A (en) * | 1994-11-25 | 1996-05-28 | General Electric Company | Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
DK0821671T3 (da) | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
US5972980A (en) * | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
GB9600344D0 (en) * | 1996-01-09 | 1996-03-13 | Lilly Co Eli | Benzimidzolyl neuropeptide y receptor antagonists |
ES2175415T3 (es) | 1996-07-18 | 2002-11-16 | Pfizer | Inhibidores de metaloproteasas matriciales basados en fosfinato. |
EA199900139A1 (ru) | 1996-08-23 | 1999-08-26 | Пфайзер, Инк. | Производные арилсульфониламиногидроксамовой кислоты |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
EA002594B1 (ru) | 1997-02-03 | 2002-06-27 | Пфайзер Продактс Инк. | Производные арилсульфониламиногидроксамовой кислоты |
CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
JP3710489B2 (ja) | 1997-02-11 | 2005-10-26 | ファイザー・インク | アリールスルホニルヒドロキサム酸誘導体 |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
EP0993437B1 (en) | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
US6534503B1 (en) * | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
ATE292462T1 (de) | 1999-01-07 | 2005-04-15 | Warner Lambert Co | Behandlung von asthma anhand von mek-inhibitoren |
HUP0104933A3 (en) | 1999-01-07 | 2003-12-29 | Warner Lambert Co | Antiviral method using mek inhibitors |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
JP2002534446A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 4′ヘテロアリールジアリールアミン |
SK9822001A3 (en) | 1999-01-13 | 2002-08-06 | Warner Lambert Co | 1-heterocycle substituted diarylamines, pharmaceutical compositions based thereon and their use in therapy |
JP2000204077A (ja) | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
ATE311363T1 (de) | 1999-01-13 | 2005-12-15 | Warner Lambert Co | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
US7030119B1 (en) * | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
HUP0202623A3 (en) | 1999-07-16 | 2003-03-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
WO2001005390A2 (en) * | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
AU5785900A (en) | 1999-07-16 | 2001-02-05 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
WO2001005393A2 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
WO2001021634A1 (en) | 1999-09-21 | 2001-03-29 | Lion Bioscience Ag | Benzimidazole derivatives and combinatorial libraries thereof |
CA2403017A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
US7001905B2 (en) | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
GEP20053496B (en) * | 2000-07-19 | 2005-04-25 | Warner Lambert Co | Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids |
SK2072003A3 (en) | 2000-08-25 | 2004-01-08 | Warner Lambert Co | Process for making N-aryl-anthranilic acids and their derivatives |
AU2002210714A1 (en) | 2000-11-02 | 2002-06-11 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
JP2004515496A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
WO2002072548A2 (en) * | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
US20040039208A1 (en) | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
WO2003024899A2 (en) * | 2001-09-17 | 2003-03-27 | Bristol-Myers Squibb Company | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) |
AU2002348791A1 (en) | 2001-12-21 | 2003-07-09 | Warner-Lambert Company Llc | Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof |
BR0307060A (pt) | 2002-01-23 | 2004-10-26 | Warner Lambert Co | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
NZ535158A (en) | 2002-03-13 | 2007-06-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as MEK inhibitors |
AU2003220202A1 (en) * | 2002-03-13 | 2003-09-29 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
DE10238002A1 (de) * | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | Benzimidazolderivate |
WO2004022060A2 (en) * | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders |
US20040127395A1 (en) * | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
BRPI0412851A (pt) | 2003-07-24 | 2006-10-03 | Warner Lambert Co | benzamidazóis de n-metila-substituìdos |
DE102005032379A1 (de) | 2005-07-08 | 2007-01-11 | Conti Temic Microelectronic Gmbh | Zugangskontrollsystem für ein Kraftfahrzeug |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
US9867825B2 (en) | 2012-12-20 | 2018-01-16 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
-
2003
- 2003-03-13 NZ NZ535158A patent/NZ535158A/en not_active IP Right Cessation
- 2003-03-13 EP EP09011388.7A patent/EP2130536B1/en not_active Expired - Lifetime
- 2003-03-13 PL PL401637A patent/PL401637A1/pl unknown
- 2003-03-13 CN CNB038107546A patent/CN100519539C/zh not_active Expired - Lifetime
- 2003-03-13 PT PT90113895T patent/PT2130537E/pt unknown
- 2003-03-13 DK DK03714148.8T patent/DK1482932T3/da active
- 2003-03-13 DE DE60330227T patent/DE60330227D1/de not_active Expired - Lifetime
- 2003-03-13 PL PL401635A patent/PL233177B1/pl unknown
- 2003-03-13 PT PT151771896T patent/PT3000810T/pt unknown
- 2003-03-13 KR KR1020047014182A patent/KR100984595B1/ko active IP Right Grant
- 2003-03-13 KR KR1020107007537A patent/KR100984613B1/ko active Protection Beyond IP Right Term
- 2003-03-13 ES ES15177189.6T patent/ES2635666T3/es not_active Expired - Lifetime
- 2003-03-13 WO PCT/US2003/007864 patent/WO2003077914A1/en active Application Filing
- 2003-03-13 SI SI200332221T patent/SI2130537T1/sl unknown
- 2003-03-13 SI SI200332449T patent/SI2275102T1/sl unknown
- 2003-03-13 SI SI200332546T patent/SI3000810T1/sl unknown
- 2003-03-13 IL IL16399503A patent/IL163995A0/xx unknown
- 2003-03-13 US US10/387,879 patent/US20030232869A1/en not_active Abandoned
- 2003-03-13 SI SI200331731T patent/SI1482932T1/sl unknown
- 2003-03-13 PL PL401638A patent/PL401638A1/pl unknown
- 2003-03-13 EP EP15177189.6A patent/EP3000810B1/en not_active Revoked
- 2003-03-13 TW TW099113360A patent/TWI350285B/zh not_active IP Right Cessation
- 2003-03-13 PT PT100116912T patent/PT2275102E/pt unknown
- 2003-03-13 PT PT03714148T patent/PT1482932E/pt unknown
- 2003-03-13 PL PL401636A patent/PL233493B1/pl unknown
- 2003-03-13 SG SG2011042850A patent/SG194238A1/en unknown
- 2003-03-13 PA PA20038569301A patent/PA8569301A1/es unknown
- 2003-03-13 ES ES10011691.2T patent/ES2549159T3/es not_active Expired - Lifetime
- 2003-03-13 CA CA002478374A patent/CA2478374C/en not_active Expired - Lifetime
- 2003-03-13 DK DK09011389.5T patent/DK2130537T3/da active
- 2003-03-13 JP JP2003575967A patent/JP4093966B2/ja not_active Expired - Lifetime
- 2003-03-13 AU AU2003218157A patent/AU2003218157C1/en active Active
- 2003-03-13 ZA ZA200407220A patent/ZA200407220B/xx unknown
- 2003-03-13 SG SG2013013339A patent/SG2013013339A/en unknown
- 2003-03-13 EP EP03714148A patent/EP1482932B1/en not_active Expired - Lifetime
- 2003-03-13 CN CN2009101492905A patent/CN101633644B/zh not_active Expired - Lifetime
- 2003-03-13 EP EP09011389A patent/EP2130537B1/en not_active Expired - Lifetime
- 2003-03-13 ES ES03714148T patent/ES2335276T3/es not_active Expired - Lifetime
- 2003-03-13 EP EP10011691.2A patent/EP2275102B1/en not_active Expired - Lifetime
- 2003-03-13 KR KR1020107007539A patent/KR100984573B1/ko active IP Right Grant
- 2003-03-13 DK DK10011691.2T patent/DK2275102T3/en active
- 2003-03-13 CN CN2008101903429A patent/CN101486682B/zh not_active Expired - Lifetime
- 2003-03-13 AT AT03714148T patent/ATE449605T1/de active
- 2003-03-13 DO DO2003000613A patent/DOP2003000613A/es unknown
- 2003-03-13 DK DK15177189.6T patent/DK3000810T3/en active
- 2003-03-13 AR ARP030100887A patent/AR038971A1/es active IP Right Grant
- 2003-03-13 TW TW099113379A patent/TWI343377B/zh not_active IP Right Cessation
- 2003-03-13 MX MXPA04008893A patent/MXPA04008893A/es active IP Right Grant
- 2003-03-13 UA UA20040907722A patent/UA77765C2/uk unknown
- 2003-03-13 ES ES09011389T patent/ES2394347T3/es not_active Expired - Lifetime
- 2003-03-13 HU HUE10011691A patent/HUE025767T2/en unknown
- 2003-03-13 ES ES09011388T patent/ES2407849T3/es not_active Expired - Lifetime
- 2003-03-13 SG SG200608672-2A patent/SG148857A1/en unknown
- 2003-03-13 TW TW092105718A patent/TWI338685B/zh not_active IP Right Cessation
- 2003-03-13 PL PL377628A patent/PL230179B1/pl unknown
- 2003-03-13 CN CN200910149291XA patent/CN101633645B/zh not_active Expired - Lifetime
- 2003-12-12 BR BR122018007328A patent/BR122018007328B8/pt active IP Right Grant
-
2004
- 2004-09-09 IL IL163995A patent/IL163995A/en active IP Right Grant
- 2004-09-09 IS IS7442A patent/IS2748B/is unknown
-
2005
- 2005-02-18 US US11/061,336 patent/US7425637B2/en not_active Expired - Lifetime
- 2005-04-26 HK HK05103569.0A patent/HK1070823A1/xx not_active IP Right Cessation
-
2007
- 2007-10-09 JP JP2007263512A patent/JP2008019277A/ja active Pending
-
2008
- 2008-01-29 JP JP2008017547A patent/JP5102642B2/ja not_active Expired - Lifetime
- 2008-03-18 US US12/050,847 patent/US7576114B2/en not_active Expired - Lifetime
- 2008-03-18 US US12/050,827 patent/US7777050B2/en not_active Expired - Lifetime
-
2009
- 2009-10-07 AU AU2009222613A patent/AU2009222613B2/en active Active
-
2010
- 2010-01-13 CY CY20101100037T patent/CY1109727T1/el unknown
- 2010-03-10 IL IL204419A patent/IL204419A/en active IP Right Grant
- 2010-03-10 IL IL204420A patent/IL204420A/en active Protection Beyond IP Right Term
- 2010-06-09 HK HK10105717.9A patent/HK1141976A1/xx not_active IP Right Cessation
- 2010-06-28 US US12/824,521 patent/US8193229B2/en not_active Expired - Fee Related
- 2010-06-28 US US12/824,547 patent/US8193230B2/en not_active Expired - Fee Related
- 2010-06-28 US US12/824,477 patent/US8003805B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,497 patent/US7973170B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,559 patent/US8178693B2/en not_active Expired - Fee Related
- 2010-06-29 US US12/826,158 patent/US8193231B2/en not_active Expired - Fee Related
-
2011
- 2011-04-20 DO DO2011000110A patent/DOP2011000110A/es unknown
- 2011-04-20 DO DO2011000109A patent/DOP2011000109A/es unknown
- 2011-06-16 IS IS8960A patent/IS2998B/is unknown
- 2011-06-16 IS IS8959A patent/IS2990B/is unknown
- 2011-06-16 IS IS8961A patent/IS2999B/is unknown
- 2011-07-13 HK HK11107302.5A patent/HK1153139A1/zh not_active IP Right Cessation
-
2012
- 2012-05-03 US US13/463,487 patent/US8513293B2/en not_active Expired - Lifetime
- 2012-08-24 JP JP2012184708A patent/JP5498546B2/ja not_active Expired - Lifetime
- 2012-08-29 CL CL2012002380A patent/CL2012002380A1/es unknown
- 2012-08-29 CL CL2012002381A patent/CL2012002381A1/es unknown
-
2013
- 2013-01-28 DO DO2013000023A patent/DOP2013000023A/es unknown
- 2013-02-25 AR ARP130100567A patent/AR090143A2/es unknown
- 2013-02-25 AR ARP130100568A patent/AR090144A2/es unknown
-
2017
- 2017-07-27 CY CY20171100805T patent/CY1119136T1/el unknown
-
2019
- 2019-02-12 LU LU00100C patent/LUC00100I2/fr unknown
- 2019-03-01 HU HUS1900011C patent/HUS1900011I1/hu unknown
- 2019-03-07 LT LTPA2019007C patent/LTC1482932I2/lt unknown
- 2019-03-13 BE BE2019C510C patent/BE2019C510I2/fr unknown
- 2019-03-15 NL NL300974C patent/NL300974I2/nl unknown
- 2019-03-18 CY CY2019012C patent/CY2019012I2/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
US6506798B1 (en) * | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
US20030078428A1 (en) * | 1997-07-01 | 2003-04-24 | Barrett Stephen Douglas | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
US6469004B1 (en) * | 1999-01-13 | 2002-10-22 | Warner-Lambert Company | Benzoheterocycles and their uses as MEK inhibitors |
US20030092748A1 (en) * | 1999-01-13 | 2003-05-15 | Barrett Stephen Douglas | Benzenesulfonamide derivatives and their use as MEK inhibitors |
Cited By (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8513293B2 (en) | 2002-03-13 | 2013-08-20 | Array Biopharma Inc. | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
US20060030610A1 (en) * | 2003-09-03 | 2006-02-09 | Kevin Koch | Method of treating inflammatory diseases |
US20050054701A1 (en) * | 2003-09-03 | 2005-03-10 | Eli Wallace | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
US7230099B2 (en) | 2003-09-03 | 2007-06-12 | Array Biopharma, Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US20110183981A1 (en) * | 2003-11-19 | 2011-07-28 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
US20050250782A1 (en) * | 2003-11-19 | 2005-11-10 | Marlow Allison L | Heterocyclic inhibitors of MEK and methods of use thereof |
US20050256123A1 (en) * | 2003-11-19 | 2005-11-17 | Marlow Allison L | Heterocyclic inhibitors of MEK and methods of use thereof |
WO2005051300A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
EP1689406A2 (en) * | 2003-11-19 | 2006-08-16 | Array Biopharma, Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
EP1689406A4 (en) * | 2003-11-19 | 2007-01-17 | Array Biopharma Inc | HETEROCYCLIC INHIBITORS OF MEK AND METHOD FOR THEIR APPLICATION |
US20070112038A1 (en) * | 2003-11-19 | 2007-05-17 | Marlow Allison L | Heterocyclic inhibitors of MEK and methods of use thereof |
US8431574B2 (en) | 2003-11-19 | 2013-04-30 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US8268852B2 (en) | 2003-11-19 | 2012-09-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US8211920B2 (en) | 2003-11-19 | 2012-07-03 | Array Biopharma Inc. | 6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof |
US8211921B2 (en) | 2003-11-19 | 2012-07-03 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use |
US8101611B2 (en) | 2003-11-19 | 2012-01-24 | Array Biopharma Inc. | Substituted pyridazines inhibitors of MEK |
US20050153942A1 (en) * | 2003-11-19 | 2005-07-14 | Eli Wallace | Heterocyclic inhibitors of MEK and methods of use thereof |
US7485643B2 (en) | 2003-11-19 | 2009-02-03 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US20090131435A1 (en) * | 2003-11-19 | 2009-05-21 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use |
US20050130976A1 (en) * | 2003-11-19 | 2005-06-16 | Eli Wallace | Bicyclic inhibitors of MEK and methods of use thereof |
US20090143579A1 (en) * | 2003-11-19 | 2009-06-04 | Array Biopharma Inc. | Heterocyclic Inhibitors of MEK and Methods of Use Thereof |
US20090143389A1 (en) * | 2003-11-19 | 2009-06-04 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
US7576072B2 (en) | 2003-11-19 | 2009-08-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7598383B2 (en) | 2003-11-19 | 2009-10-06 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US20050130943A1 (en) * | 2003-11-19 | 2005-06-16 | Eli Wallace | Bicyclic inhibitors of MEK and methods of use thereof |
US20110178136A1 (en) * | 2003-11-19 | 2011-07-21 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
EP2251327A2 (en) | 2003-11-19 | 2010-11-17 | Array Biopharma, Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7772234B2 (en) | 2003-11-19 | 2010-08-10 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US8680114B2 (en) | 2003-11-21 | 2014-03-25 | Array Biopharma, Inc. | AKT protein kinase inhibitors |
US20100168123A1 (en) * | 2003-11-21 | 2010-07-01 | Mitchell Ian S | Akt protein kinase inhibitors |
US20050130954A1 (en) * | 2003-11-21 | 2005-06-16 | Mitchell Ian S. | AKT protein kinase inhibitors |
US20050171182A1 (en) * | 2003-12-11 | 2005-08-04 | Roger Briesewitz | Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
US8299076B2 (en) | 2005-05-18 | 2012-10-30 | Array Biopharma Inc. | Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide |
US20080280957A1 (en) * | 2005-05-18 | 2008-11-13 | Array Biopharma, Inc. | Heterocyclic Inhibitors of Mek and Methods of Use Thereof |
EP2364973A1 (en) | 2005-05-18 | 2011-09-14 | Array Biopharma, Inc. | Heterocyclic inhibitors of MEK and Methods of use thereof |
EP2361905A1 (en) | 2005-05-18 | 2011-08-31 | Array Biopharma Inc. | Heterocyclic Inhibitors of MEK and methods of use thereof |
US8039637B2 (en) | 2005-06-23 | 2011-10-18 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
US8383832B2 (en) | 2005-06-23 | 2013-02-26 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
US9024040B2 (en) | 2005-06-23 | 2015-05-05 | Array Biopharma Inc. | Processes for preparing benzimidazole compounds |
US20100130748A1 (en) * | 2005-06-23 | 2010-05-27 | Array Biopharma Inc. | Snar process for preparing benzimidazole compounds |
CN101248060B (zh) * | 2005-06-23 | 2014-09-10 | 阵列生物制药公司 | 用于制备苯并咪唑化合物的方法 |
US8501956B2 (en) | 2005-06-23 | 2013-08-06 | Array Biopharma Inc. | Benzimidazole compounds |
US20100145065A1 (en) * | 2005-06-23 | 2010-06-10 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
WO2007002157A3 (en) * | 2005-06-23 | 2007-11-01 | Array Biopharma Inc | Process for preparing benzimidazole compounds |
TWI391380B (zh) * | 2005-06-23 | 2013-04-01 | Array Biopharma Inc | 製備苯并咪唑化合物之方法 |
AU2006262259B2 (en) * | 2005-06-23 | 2013-03-14 | Array Biopharma Inc. | Process for preparing benzimidazole compounds |
US8183385B2 (en) | 2005-06-23 | 2012-05-22 | Array Biopharma Inc. | SNAR process for preparing benzimidazole compounds |
US20100016393A1 (en) * | 2005-12-21 | 2010-01-21 | Demattei John | Novel hydrogen sulfate salt |
US9562017B2 (en) | 2005-12-21 | 2017-02-07 | AsrtaZeneca AB | Hydrogen sulfate salt |
US20090030058A1 (en) * | 2005-12-21 | 2009-01-29 | Mohammed Pervez | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
US9156795B2 (en) | 2005-12-21 | 2015-10-13 | Array Biopharma, Inc. | Hydrogen sulfate salt |
US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
US20080058327A1 (en) * | 2006-07-06 | 2008-03-06 | Mitchell Ian S | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US9359340B2 (en) | 2006-07-06 | 2016-06-07 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US9303040B2 (en) | 2006-07-06 | 2016-04-05 | Array Biopharma Inc. | Substituted piperazines as AKT inhibitors |
US8853199B2 (en) | 2006-07-06 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US20080051399A1 (en) * | 2006-07-06 | 2008-02-28 | Mitchell Ian S | Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US8846681B2 (en) | 2006-07-06 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8003651B2 (en) | 2006-07-06 | 2011-08-23 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US20100069381A1 (en) * | 2006-08-03 | 2010-03-18 | Fumio Itoh | Gsk-3betainhibitor |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US20110160221A1 (en) * | 2007-07-05 | 2011-06-30 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US8618097B2 (en) | 2007-07-05 | 2013-12-31 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US20110065716A1 (en) * | 2008-01-09 | 2011-03-17 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US8853216B2 (en) | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
US8835434B2 (en) | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US20100292244A1 (en) * | 2008-01-09 | 2010-11-18 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2011047788A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
WO2012085244A1 (fr) | 2010-12-23 | 2012-06-28 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
US9346789B2 (en) | 2011-04-01 | 2016-05-24 | Genentech, Inc. | Combinations of AKT inhibitor compounds and abiraterone, and methods of use |
US9150548B2 (en) | 2011-04-01 | 2015-10-06 | Genentech, Inc. | Combinations of AKT inhibitor compounds and vemurafenib, and methods of use |
US9150549B2 (en) | 2011-04-01 | 2015-10-06 | Genentech, Inc. | Combinations of AKT inhibitor compounds and erlotinib, and methods of use |
US9610289B2 (en) | 2011-04-01 | 2017-04-04 | Genentech, Inc. | Combinations of AKT inhibitor compounds and erlotinib, and methods of use |
US9682082B2 (en) | 2011-04-01 | 2017-06-20 | Genentech, Inc. | Combinations of AKT and MEK inhibitor compounds, and methods of use |
US9717730B2 (en) | 2011-04-01 | 2017-08-01 | Genentech, Inc. | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use |
US10092567B2 (en) | 2011-04-01 | 2018-10-09 | Genentech, Inc. | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1482932B1 (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
US7235537B2 (en) | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARRAY BIOPHARMA, INC., COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WALLACE, ELI M.;LYSSIKATOS, JOSEPH P.;MARLOW, ALLISON L.;AND OTHERS;REEL/FRAME:014223/0609 Effective date: 20030610 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARRAY BIOPHARMA, INC.;REEL/FRAME:037387/0824 Effective date: 20150723 |
|
AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 037387 FRAME 0824. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:ARRAY BIOPHARMA, INC.;REEL/FRAME:038057/0759 Effective date: 20150723 Owner name: ARRAY BIOPHARMA, INC., COLORADO Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 037387 FRAME 0824. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:ARRAY BIOPHARMA, INC.;REEL/FRAME:038057/0759 Effective date: 20150723 |